

A. Biographical and Bibliographic Information

IDENTIFYING DATA

1. **Name:** Andrei Horia Iagaru

B. ACADEMIC HISTORY

1. Colleges and Universities Attended

Oct. 1994 - Nov. 2000 Carol Davila Medical School, Bucharest, Romania, M.D.

2. Scholarships and Academic Honors (Excludes Post Degree Awards)

1994 High School Valedictorian

1995, 1997, 1999, 2000 Carol Davila Excellence Scholarship/Dean's Honor List

1996 Education Secretary's Emeritus Scholarship

3. Postdoctoral Residency and Training

Jun. 2003 - Jun. 2004 Drexel University College of Medicine, Graduate Hospital, Department of Medicine (Intern)

Jul. 2004 – Jun. 2005 Keck School of Medicine of USC, LSC+USC Medical Center, Radiology Department, Division of Nuclear Medicine (Chief Resident)

Jul. 2005 – Jun. 2006 Stanford School of Medicine, Stanford Hospital and Clinics, Radiology Department, Division of Nuclear Medicine (Resident)

Jul. 2006 – Jun. 2007 Stanford School of Medicine, Stanford Hospital and Clinics, Radiology Department, Division of Nuclear Medicine (PET/CT Fellow)

4. Certifications

Oct. 2006 American Board of Nuclear Medicine

Feb. 2012 Radiography X-Ray Supervisor and Operator, ARRT

C. EMPLOYMENT HISTORY

1. Academic Appointments

Jul. 2004 – Jun. 2005 Clinical Instructor, Department of Radiology, Division of Nuclear Medicine Keck School of Medicine, University of Southern California

Jul. 2007 – Aug. 2010 Clinical Instructor, Department of Radiology, Division of Nuclear Medicine, Stanford School of Medicine, Stanford University Medical Center

Sep. 2010 – May 2014 Assistant Professor (MCL), Department of Radiology, Division of Nuclear Medicine, Stanford School of Medicine, Stanford University Medical Center

Jun. 2014 – Jan. 2019 Associate Professor (MCL), Department of Radiology, Division of Nuclear Medicine, Stanford School of Medicine, Stanford University Medical Center

Feb. 2019 – present Professor (MCL), Department of Radiology, Division of Nuclear Medicine, Stanford School of Medicine, Stanford University Medical Center

D. PUBLIC AND PROFESSIONAL SERVICE

1. Committees and Appointments

2006 - present	Ad-Hoc Reviewer: <i>Radiology; American Journal of Roentgenology; Journal of Nuclear Medicine; European Journal of Nuclear Medicine and Molecular Biology; Molecular Imaging and Biology; Annals of Nuclear Medicine; Nuclear Medicine Communications; Journal of Computer Assisted Tomography; Haematologica; British Journal of Cancer; Indian Journal of Cancer; American Journal of Neuroradiology</i>
2009 - present	Editorial Board: <i>PLoS ONE; American Journal of Nuclear Medicine and Molecular Imaging; Clinical Nuclear Medicine; Quantitative Imaging in Medicine and Surgery; World Journal of Radiology; Journal of Nuclear Medicine; European Journal of Nuclear Medicine and Molecular Biology</i>
2011 - 2014	Academic Editor: <i>PLoS ONE</i>
2009 - present	Member: <i>Radiology Residency Education Committee; Clinical Radiation Safety Committee; LPCH Transformation Project Committee - Nuclear Medicine /PET-CT;</i>
2011 - 2019	Program Director: <i>Stanford Nuclear Medicine Residency Program</i>
2012 - 2016	Co-Chief: <i>Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center</i>
2016 - present	Chief: <i>Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center</i>
2011 - 2016	Co-Chair: <i>Society of Nuclear Medicine and Molecular Imaging Outreach Committee</i>
2012 - 2016	Co-Chair: <i>Society of Nuclear Medicine and Molecular Imaging Targeted Radionuclide Therapy Working Group</i>
2013 - 2015	Co-Chair: <i>Society of Nuclear Medicine and Molecular Imaging PET/MRI Task Force</i>
2011 - 2015	Ambassador to ASCO: <i>Society of Nuclear Medicine and Molecular Imaging</i>
2013 - 2015	Member: <i>Board of Directors, PET Center of Excellence (Society of Nuclear Medicine and Molecular Imaging)</i>
2012 - 2016	Member: <i>Society of Nuclear Medicine and Molecular Imaging Committee on Public Relations</i>
2013 - present	Member: <i>National Comprehensive Cancer Network Thyroid Cancer Panel</i>
2012 - present	Member: <i>Scientific Review Committee, Stanford Cancer Institute</i>
2007 - 2013	Associate Member: <i>Stanford Cancer Institute</i>
2013 - present	Member: <i>Stanford Cancer Institute</i>
2013 - present	Associate Member: <i>Canary Center at Stanford for Early Cancer Detection</i>
2014 - present	Co-Director: <i>PET/MRI Research Program at Stanford University</i>
2014 - present	Member: <i>Bio-X</i>

2016 - present	Director: <i>American Board of Nuclear Medicine</i>
2017 - present	Member: <i>Society of Nuclear Medicine and Molecular Imaging Finance Committee</i>
2017 - present	Member: <i>Society of Nuclear Medicine and Molecular Imaging Awards Committee</i>
2017 - present	Associate Editor (Molecular Imaging): <i>Radiology</i>
2018 - present	Member: <i>ACGME Nuclear Medicine Residency Review Committee</i>
2021 - present	Associate Editor: <i>European Journal of Nuclear Medicine and Molecular Biology</i>

E. POST-DEGREE HONORS AND AWARDS

1. Honors and Awards

2007	Travel Grant Award, ACNP Annual Meeting: “ ¹⁸ F FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan?” (first author)
2008	Best Essay Award, ACNP Annual Meeting: “ ¹³¹ I-Tositumomab (Bexxar [®]) vs. ⁹⁰ Y-Ibritumomab (Zevalin [®]) in Refractory/Relapsed Non-Hodgkin’s Lymphoma” (first author)
2008	Best Essay Award, ACNP Annual Meeting: “ ¹⁸ F FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning?” (first author)
2008	Alavi-Mandell Award, Society of Nuclear Medicine, the Journal of Nuclear Medicine (first author)
2008	Outstanding Teaching Award, Stanford Radiology Residency Program
2009	Alavi-Mandell Award, Society of Nuclear Medicine, the Journal of Nuclear Medicine (first author)
2009	Image of the Year Award, Society of Nuclear Medicine (first author)
2009	Developmental Cancer Research Award, Stanford Cancer Center
2009	Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author)
2010	Best Essay Award, ACNM Annual Meeting: “Combined ¹⁸ F NaF and ¹⁸ F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study” (first author)
2010	Alavi-Mandell Award, Society of Nuclear Medicine, The Journal of Nuclear Medicine (first author)
2011	Best Essay Award, ACNM Annual Meeting: “Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for ¹⁸ F FDG PET/CT Surveillance?” (first author)
2011	Winner – Young Professional Tournament, 1 st Sino-American Conference on Nuclear Medicine (first author)
2011	Radiopharmaceutical Sciences Council Travel Grant, SNM Annual Meeting (first author)
2011	Nuclear Oncology Council Young Investigator Award, 2 nd Place, SNM Annual Meeting (first author)

2011	Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (senior author)
2013	Winner – Young Professional Tournament, 2 nd Sino-American Conference on Nuclear Medicine (senior author)
2013	Fellow, American College of Nuclear Medicine
2013	Faculty Fellowship Award, Stanford Center at Peking University
2013	Stanford Faculty Fellows Program
2014	Poster Award, ACNM Annual Meeting: “Combined ¹⁸ F NaF and ¹⁸ F FDG PET/CT Evaluation of Sarcoma Patients” (senior author)
2014	Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author)
2015	Winner, ACNM/SNMMI Exchange Program Award: “A Prospective, Matched Comparison Study of SUV Values from non-TOF vs. TOF PET/CT Scanners” (senior author)
2015	Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author)
2016	Editor’s Recognition Award, Clinical Nuclear Medicine
2017	Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (senior author)
2018	Clinician of the Year, Department of Radiology, Stanford University
2020	The Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM Annual Meeting

2. Professional Membership Associations

2005	Society of Nuclear Medicine and Molecular Imaging
2005	Radiological Society of North America
2006	World Molecular Imaging Society
2007	European Association of Nuclear Medicine
2007	American College of Nuclear Medicine

F. SCHOLARLY PUBLICATIONS

1. Peer Reviewed Original Research Journal Articles (Total 98)

1. **Iagaru A**, Quon A, McDougall IR, Gambhir SS. Merkel Cell Carcinoma: Is There a Role for ¹⁸F FDG PET/CT? *Mol Imaging Biol.* 2006 Jul-Aug;8(4):212-7.
2. **Iagaru A**, Masamed R, Singer PA, Conti PS. ¹⁸F FDG PET and PET/CT Diagnosis of Patients with Recurrent Papillary Thyroid Cancer. *Mol Imaging Biol.* 2006 Sep-Oct;8(5):309-14.
3. **Iagaru A**, Chawla SP, Menendez LR, Conti PS. ¹⁸F FDG PET and PET/CT for Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. *Nucl Med Commun.* 2006 Oct;27(10):795-802.

4. **Iagaru A**, Quon A, McDougall IR, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas. *Clin Nucl Med*. 2006 Dec;31(12):754-760.
5. **Iagaru A**, Quon A, Johnson D, Gambhir SS, McDougall IR. ¹⁸F FDG PET/CT in the Management of Melanoma. *Mol Imaging Biol*. 2007 Jan-Feb;9(1):50-7.
6. **Iagaru A**, Masamed R, Keesara S, Conti PS. Breast MRI and ¹⁸F FDG PET/CT in the Management of Breast Cancer. *Ann Nucl Med*. 2007 Jan;21(1):33-8.
7. **Iagaru A**, Masamed R, Singer PA, Conti PS. Detection of Occult Medullary Thyroid Cancer Recurrence with ¹⁸F FDG PET and PET/CT. *Mol Imaging Biol*. 2007 Mar-Apr;9(2):72-7.
8. **Iagaru A**, Kalinyak J, McDougall IR. ¹⁸F FDG PET/CT in the Management of Thyroid Cancer. *Clin Nucl Med*. 2007 Sep;32(9):690-5.
9. **Iagaru A**, Masamed R, Chawla S, Menendez L, Fedenko A, Conti PS. ¹⁸F FDG PET and PET/CT Evaluation of Response to Neoadjuvant Chemotherapy in Musculoskeletal and Soft-Tissue Sarcomas. *Clin Nucl Med*. 2008 Jan;33(1):8-13.
10. **Iagaru A**, Gambhir SS, Goris ML. ⁹⁰Y-Ibritumomab (Zevalin[®]) Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from ¹¹¹In-Ibritumomab Pre-Treatment Imaging. *J Nucl Med*. 2008 Nov;49(11):1809-1812.
11. **Iagaru A**, Mitra ES, McDougall IR, Quon A, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Patients with Ovarian Carcinoma. *Nucl Med Commun*. 2008 Dec;29(12):1046-51.
12. **Iagaru A**, Wang, Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Response to Therapy in Lymphoma: When is the Optimal Time for the First Re-evaluation Scan? *Hell J Nucl Med*. 2008 Sep-Dec;11(3):153-6.
13. **Iagaru A**, Mitra ES, Yaghoubi S, Dick DW, Quon A, Goris ML, Gambhir SS. A Novel Strategy for a Cocktail ¹⁸F Fluoride and ¹⁸F FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot Phase Study. *J Nucl Med*. 2009 Apr;50(4):501-5.
14. **Iagaru A**, Kundu R, Jadvar H, Nagle D. Evaluation by ¹⁸F FDG PET of patients with anal squamous cell carcinoma. *Hell J Nucl Med*. 2009 Jan-Apr;12(1):26-8.
15. Mitra ES, El-Maghraby T, Rodriguez CA, Quon A, McDougall IR, Gambhir SS, **Iagaru A**. Efficacy of ¹⁸F-FDG PET/CT in the Evaluation of Patients with Recurrent Cervical Carcinoma. *Eur J Nucl Med Mol Imaging*. 2009 Dec;36(12):1952-9.
16. **Iagaru A**, Mitra ES, Ganjoo K, Knox SJ, Goris ML. ¹³¹I-Tositumomab (Bexxar[®]) vs. ⁹⁰Y-Ibritumomab (Zevalin[®]) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma. *Mol Imaging Biol*. 2010 Apr;12(2):198-203.
17. **Iagaru A**, Mitra ES, Gambhir SS. ¹⁸F FDG PET/CT in Cancers of the Head and Neck: What is the Definition of Whole-Body Scanning? *Mol Imaging Biol*. 2011 Apr;13(2):362-7.
18. Mitra ES, Goris ML, **Iagaru A**, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS. Pilot Pharmacokinetic and Dosimetric Studies of ¹⁸F FPPRGD₂: A PET Radiopharmaceutical Agent for Imaging $\alpha_v\beta_3$ Integrin Levels. *Radiology*. 2011 Jul;260(1):182-91.
19. Murphy JD, Chisholm KM, Daly ME, Wiegner EA, Truong D, **Iagaru A**, Maxim PG, Loo BW Jr, Graves EE, Kaplan MJ, Kong C, Le QT. Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. *Radiother Oncol*. 2011 Dec;101(3):356-61.
20. Sze DY, **Iagaru A**, Gambhir S, de Haan H, Reid T. Response to intraarterial oncolytic virotherapy with the Herpes virus NV-1020 evaluated by ¹⁸F fluorodeoxyglucose positron emission tomography and computed tomography. *Hum Gene Ther*. 2012 Jan;23(1):91-7.
21. Lin FI, Rao J, Mitra ES, Nallapareddy K, Chengapa A, Dick DW, Gambhir SS, **Iagaru A**. Prospective Comparison of Combined ¹⁸F FDG and ¹⁸F NaF PET/CT vs. ¹⁸F FDG PET/CT Imaging for Detection of Malignancy. *Eur J Nucl Med Mol Imaging*. 2012 Feb;39(2):262-70.
22. **Iagaru A**, Mitra ES, Dick DW, Gambhir SS. Prospective Evaluation of ^{99m}Tc MDP Scintigraphy, ¹⁸F NaF PET/CT and ¹⁸F FDG PET/CT for Detection of Skeletal Metastases. *Mol Imaging Biol*. 2012 Apr;14(2):252-9.
23. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, **Iagaru A**, Graves EE, Loo BW Jr, Le QT. Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1;83(5):1514-20.

24. Chu KP, Murphy JD, La TH, Krakow TE, **Iagaru A**, Graves EE, Hsu A, Maxim PG, Loo B, Chang DT, Le QT. Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head-and-Neck Cancer Outcomes. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1;83(5):1521-7.
25. Natarajan A, Gowrishankar G, Nielsen CH, Wang S, **Iagaru A**, Goris ML, Gambhir SS. Positron Emission Tomography of (64)Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL. *Mol Imaging Biol*. 2012 Oct;14(5):608-16.
26. Quon A, Dodd R, **Iagaru A**, de Abreu MR, Hennemann S, Neto JM, Sprinz C. Initial investigation of ¹⁸F-NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgery. *Eur J Nucl Med Mol Imaging*. 2012 Nov;39(11):1737-44.
27. **Iagaru A**, Mittra ES, Dick DW, Mosci C, Sathekge M, Prakash V, Iyer V, Lapa P, Isidoro J, de Lima JM, Gambhir SS. Combined ¹⁸F FDG and ¹⁸F NaF PET/CT Scan for Evaluation of Malignancy: Results of an International Multi-Center Trial. *J Nucl Med*. 2013 Feb;54(2):176-83.
28. **Iagaru A**, Young PM, Mittra ES, Dick DW, Herfkens R, Gambhir SS. Pilot Prospective Evaluation of ^{99m}Tc-MDP Scintigraphy, ¹⁸F NaF PET/CT, ¹⁸F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. *Clin Nucl Med*. 2013 Jul;38(7):e290-6.
29. Nair VS, Keu KV, Luttgren MS, Kolatkar A, Vasawala M, Kuschner W, Bethel K, **Iagaru A**, Hoh C, Shrager JB, Loo BW Jr, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. An Observational Study of Circulating Tumor Cells and ¹⁸F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer. *PLoS One*. 2013 Jul 5;8(7):e67733.
30. Lam MG, Louie JD, **Iagaru A**, Goris ML, Sze DY. Safety of Repeated Yttrium-90 Radioembolization. *Cardiovasc Intervent Radiol*. 2013 Oct;36(5):1320-8.
31. **Iagaru A**, Mosci C, Dick DW, Sathekge M, Lapa P, de Lima JM, Gambhir SS. Combined ¹⁸F-fluoride and ¹⁸F-FDG PET/CT: a response based on actual data from prospective studies. *Eur J Nucl Med Mol Imaging*. 2013 Dec;40(12):1922-4.
32. Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, **Iagaru A**, Ennen RE, Sze DY. Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization. *Cardiovasc Intervent Radiol*. 2013 Dec;36(6):1536-47.
33. Lam MG, Goris ML, **Iagaru A**, Mittra ES, Louie JD, Sze DY. Prognostic Utility of ⁹⁰Y Radioembolization Dosimetry Based on Fusion ^{99m}Tc-Macroaggregated Albumin-^{99m}Tc-Sulfur Colloid SPECT. *J Nucl Med*. 2013 Dec;54(12):2055-61.
34. Takehana C, Twist C, Mosci C, Mittra ES, Quon A, Gambhir SS, **Iagaru A**. ¹⁸F FDG PET/CT in the Management of Patients with Post-Transplant Lymphoproliferative Disorder. *Nucl Med Commun*. 2014 Mar;35(3):276-81.
35. **Iagaru A**, Mosci C, Shen B, Chin FT, Mittra ES, Telli ML, Gambhir SS. ¹⁸F FPPRGD₂ PET/CT: Pilot Phase Evaluation of Breast Cancer Patients. *Radiology*. 2014 Nov;273(2):549-59.
36. **Iagaru A**, Mittra E, Minamimoto R, Jamali M, Levin C, Quon A, Gold G, Herfkens R, Vasawala S, Gambhir SS, Zaharchuk G. Simultaneous whole-body time-of-flight ¹⁸F-FDG PET/MRI: a pilot study comparing SUV_{max} with PET/CT and assessment of MR image quality. *Clin Nucl Med*. 2015 Jan;40(1):1-8.
37. Sampath S, Sampath S, Mosci C, Lutz A, Willmann JK, Mittra ES, Gambhir SS, **Iagaru A**. Detection of Osseous Metastases by Combined ¹⁸F NaF/¹⁸F FDG PET/CT versus CT Alone. *Clin Nucl Med*. 2015 Mar;40(3):e173-7.
38. Natarajan A, Arksey N, **Iagaru A**, Chin FT, Gambhir SS. Validation of ⁶⁴Cu-DOTA-Rituximab Injection Preparation Under Good Manufacturing Practices: A PET Tracer for Imaging of B-Cell Non-Hodgkin Lymphoma. *Mol Imaging*. 2015 Mar 1;14(0):1-11.
39. Sabbah N, Jackson T, Mosci C, Jamali M, Minamimoto R, Quon A, Mittra ES, **Iagaru A**. ¹⁸F-Sodium Fluoride PET/CT in Oncology: An Atlas of SUVs. *Clin Nucl Med*. 2015 Apr;40(4):e228-31.
40. Smits ML, Elschot M, Sze DY, Kao YH, Nijsen JF, **Iagaru A**, de Jong HW, van den Bosch MA, Lam MG. Radioembolization Dosimetry: The Road Ahead. *Cardiovasc Intervent Radiol*. 2015 Apr;38(2):261-9.
41. Minamimoto R, Mosci C, Jamali M, Barkhodari A, Habte F, Jackson T, Mittra E, Gambhir SS, **Iagaru A**. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F NaF and ¹⁸F FDG Administration for PET/CT Imaging. *J Nucl Med*. 2015 May;56(5):688-94.
42. Loo BW Jr, Soltys SG, Wang L, Lo A, Fahimian BP, **Iagaru A**, Norton L, Shan X, Gardner E, Fogarty T, Maguire P, Al-Ahmad A, Zei P. Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia. *Circ Arrhythm Electrophysiol*. 2015 Jun;8(3):748-50.

43. Lam MG, Banerjee A, Goris ML, **Iagaru A**, Mitra ES, Louie JD, Sze DY. Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types. *Eur J Nucl Med Mol Imaging*. 2015 Jul;42(8):1192-201.
44. Jackson T, Mosci C, von Eyben R, Mitra ES, Ganjoo K, Biswal S, Gambhir SS, **Iagaru A**. Combined ^{18}F NaF and ^{18}F FDG PET/CT in the Evaluation of Sarcoma Patients. *Clin Nucl Med*. 2015 Sep;40(9):720-4.
45. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mitra E, Shen B, Chin FT, Gambhir SS, **Iagaru A**. Biodistribution of the ^{18}F FPPRGD₂ PET Radiopharmaceutical in Cancer Patients: An Atlas of SUV Measurements. *Eur J Nucl Med Mol Imaging*. 2015 Nov;42(12):1850-8.
46. **Iagaru A**, Mosci C, Mitra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS. Glioblastoma Multiforme Recurrence: An Exploratory Study of ^{18}F FPPRGD₂ PET/CT. *Radiology*. 2015 Nov;277(2):497-506.
47. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mitra E, Shen B, Chin F, Gambhir SS, **Iagaru A**. Biodistribution of the ^{18}F -FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. *Eur J Nucl Med Mol Imaging*. 2015 Nov;42(12):1850-8.
48. Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanaawala S, **Iagaru A**. Prospective Comparison of $^{99\text{m}}\text{Tc}$ -MDP Scintigraphy, Combined ^{18}F -NaF and ^{18}F -FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. *J Nucl Med*. 2015 Dec;56(12):1862-8.
49. Minamimoto R, Mitsumoto T, Miyata Y, Sunaoka F, Morooka M, Okasaki M, **Iagaru A**, Kubota K. Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image. *Nucl Med Commun*. 2016 Feb;37(2):162-70.
50. Mitra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, **Iagaru A**, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[^{18}F]Fluoropropyl)-L-Glutamate (^{18}F -FSPG) for PET/CT Imaging of Intracranial Malignancies. *PLoS One*. 2016 Feb 18;11(2):e0148628.
51. Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanaawala S, Gambhir SS, **Iagaru A**. Pilot Comparison of ^{68}Ga -RM2 PET and ^{68}Ga -PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. *J Nucl Med*. 2016 Apr;57(4):557-62.
52. Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, **Iagaru A**. Pilot prospective evaluation of ^{18}F -FPPRGD₂ PET/CT in patients with cervical and ovarian cancer. *Eur J Nucl Med Mol Imaging*. 2016 Jun;43(6):1047-55.
53. Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, Mitra ES, **Iagaru A**. Spectrum of ^{68}Ga -DOTA TATE Uptake in Patients with Neuroendocrine Tumors. 2016 Jun;41(6):e281-7.
54. Thompson HM, Minamimoto R, Jamali M, Barkhodari A, von Eyben R, **Iagaru A**. A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners. *Clin Nucl Med*. 2016 Jul;41(7):e323-6.
55. Guo HH, Moradi F, **Iagaru A**. Clinical Significance of Extra-skeletal CT Findings on ^{18}F -NaF PET/CT Performed for Osseous Metastatic Disease Evaluation. *Nucl Med Commun*. 2016 Sep;37(9):975-82.
56. Minamimoto R, Levin C, Jamali M, Holley D, Barkhodari A, Zaharchuk G, **Iagaru A**. Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI. *Mol Imaging Biol*. 2016 Oct;18(5):776-81.
57. Minamimoto R, **Iagaru A**, Jamali M, Holley D, Barkhodari A, Vasanaawala S, Zaharchuk G. Conspicuity of Malignant Lesions on PET/CT and Simultaneous Time-Of-Flight PET/MRI. *PLoS One*. 2017 Jan 19;12(1):e0167262.
58. Lapa P, Marques M, Costa G, **Iagaru A**, Pedrosa de Lima J. Assessment of skeletal tumour burden on ^{18}F -NaF PET/CT using a new quantitative method. *Nucl Med Commun*. 2017 Apr;38(4):325-332.
59. Baratto L, Park S, Hatami N, Davidzon G, Srinivas SS, Gambhir SS, **Iagaru A**. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. *PLoS One*. Jun 5;12(6):e0178936.
60. Ter Voert EE, Veit-Haibach P, Ahn S, Wiesinger F, Khalighi MM, Levin CS, **Iagaru A**, Zaharchuk G, Huellner M, Delso G. Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. *Eur J Nucl Med Mol Imaging*. 2017 Jul;44(7):1223-1233.
61. Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, **Iagaru A**, Herfkens R. Initial Experience With Simultaneous ^{18}F -FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis. *Clin Nucl Med*. 2017 Jul;42(7):e328-e334.

62. Minamimoto R, Xu G, Jamali M, Holley D, Barkhodari A, Zaharchuk G, **Iagaru A**. Semi-quantitative assessment of ^{18}F FDG uptake in the normal skeleton: comparison between PET/CT and time of flight simultaneous PET/MRI. *AJR Am J Roentgenol*. 2017 Nov;209(5):1136-1142.
63. Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, **Iagaru A**, Herfarth K, Haberkorn U, Debus J, Giesel FL. ^{68}Ga -PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. *J Nucl Med*. 2017 Dec;58(12):1943-1948.
64. Baratto L, Davidzon GA, Moghbel M, Hatami N, **Iagaru A**, Mittra ES. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma. *Clin Nucl Med*. 2018 Jan;43(1):1-8.
65. Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, **Iagaru A**, Brown A Jr., Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. *Oncologist*. 2018 Feb;23(2):193-202.
66. Obara P, Loening A, Taviani V, **Iagaru A**, Hargreaves BA, Vasanawala S. Relative value of three whole-body MR approaches for PET-MR, including gadofosveset-enhanced MR, in comparison to PET-CT. *Clin Imaging*. 2018 Mar - Apr;48:62-68.
67. Orthey P, Yu D, Van Natta ML, Ramsey FV, Diaz JR, Bennett PA, **Iagaru A**, Fragomeni RS, McCallum RW, Sarosiek I, Hasler WL, Farrugia G, Grover M, Koch KL, Nguyen L, Snape WJ, Abell TL, Pasricha PJ, Tonascia J, Hamilton F, Parkman HP, Maurer AH; NIH Gastroparesis Consortium. Intra-gastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. *J Nucl Med*. 2018 Apr;59(4):691-697.
68. Sonni I, Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, **Iagaru A**. Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality. *EJNMMI Phys*. 2018 Apr 18;5(1):9.
69. Lantos J, Mittra E, Levin CS, **Iagaru A**. Standard OSEM vs. Regularized PET Image Reconstruction: Qualitative and Quantitative Comparison Using Phantom Data and Various Clinical Radiopharmaceuticals. *Am J Nucl Med Mol Imaging*. 2018 Apr 25;8(2):110-118.
70. Minamimoto R, Sonni I, Hancock S, Vasanawala S, Loening A, Gambhir SS, **Iagaru A**. Prospective Evaluation of ^{68}Ga -RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging. *J Nucl Med*. 2018 May;59(5):803-808.
71. Kogan F, Fan AP, Monu U, **Iagaru A**, Hargreaves BA, Gold GE. Quantitative imaging of bone-cartilage interactions in ACL-injured patients with PET-MRI. *Osteoarthritis Cartilage*. 2018 Jun;26(6):790-796.
72. Baratto L, Park SY, Hatami N, Gulaka P, Vasanawala S, Yohannan TK, Herfkens R, Witteles R, **Iagaru A**. ^{18}F -florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. *EJNMMI Res*. 2018 Jul 24;8(1):66.
73. Park S, Zacharias C, Harrison C, Fan R, Kunder C, Ghanouni P, Sonn P, **Iagaru A**. ^{68}Ga -PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate or High-Risk Prostate Cancer. *Radiology*. 2018 Aug;288(2):495-505.
74. Wangerin KA, Baratto L, Khalighi MM, Hope TA, Gulaka PK, Deller TW, **Iagaru A**. Clinical evaluation of ^{68}Ga -PSMA-11 and ^{68}Ga -RM2 PET images reconstructed with an improved scatter correction algorithm. *AJR Am J Roentgenol*. 2018 Sep;211(3):655-660.
75. Li D, Zhang J, Ji N, Zhao X, Zheng K, Qiao Z, Li F, Lang L, **Iagaru A**, Niu G, Zhu Z, Chen X. Combined ^{68}Ga -NOTA-PRGD₂ and ^{18}F -FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma. *Clin Nucl Med*. 2018 Sep;43(9):648-654.
76. Hong S, Mosci C, Akatsu H, Basina M, Dosiou C, McDougall IR, **Iagaru A**. Diagnostic ^{123}I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients with Papillary Thyroid Cancer: Implications for Clinical Management. *Clin Nucl Med*. 2018 Oct;43(10):705-709.
77. Bachawal SV, Park JM, Valluru KS, Loft MD, Felt SA, Vilches-Moure JG, Saenz YF, Daniel B, **Iagaru A**, Sonn G, Cheng Z, Spielman DM, Willmann JK. Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model. *Mol Imaging Biol*. 2019 Feb 21.
78. Ning N, Guo HH, **Iagaru A**, Mittra E, Fowler M, Witteles R. Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis. *J Card Fail*. 2019 Apr;25(4):307-311.

79. Toriihara A, Duan H, Thompson HM, Park S, Hatami N, Baratto L, Fan AC, **Iagaru A**. ^{18}F -FPPRGD₂ PET/CT in patients with metastatic renal cell cancer. *Eur J Nucl Med Mol Imaging*. 2019 Jul;46(7):1518-1523.
80. Twist CJ, Hiniker SM, Gratzinger D, Gutkin PM, Merriott DJ, **Iagaru A**, Link MP, Donaldson SS. Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children. *Pediatr Blood Cancer*. 2019 Aug;66(8):e27803.
81. Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz P, **Iagaru A**. Prognostic value of volumetric parameters calculated from ^{68}Ga -DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2019 Oct;46(11):2244-2251.
82. Baratto L, Duan H, Laudicella R, Toriihara A, Hatami N, Ferri V, **Iagaru A**. Physiological ^{68}Ga -RM2 Uptake in Patients with Biochemically Recurrent Prostate Cancer: An Atlas of Semi-Quantitative Measurements. *Eur J Nucl Med Mol Imaging*. 2020 Jan;47(1):115-122.
83. Bachawal SV, Park JM, Valluru KS, Loft MD, Felt SA, Vilches-Moure JG, Saenz YF, Daniel B, **Iagaru A**, Sonn G, Cheng Z, Spielman DM, Willmann JK. Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model. *Mol Imaging Biol*. 2019 Oct;21(5):861-870.
84. Christian PE, Williams SP, Burrel L, Castaneda P, Albiani J, Sandella N, **Iagaru A**, Hoffman JM, de Crespigny A, Bohorquez SS. Optimization of ^{89}Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic Phantom. *J Nucl Med Technol*. 2020 Mar;48(1):54-57.
85. Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, Guo HH, Haywood T, Abou-Elkacem L, Baratto L, Habte F, Devulapally R, Witney TH, Cheng Y, Tikole S, Chakraborti S, Nix J, Bonagura CA, Hatami N, Mooney JJ, Desai T, Turner S, Gaster RS, Otte A, Visser BC, Poultsides GA, Norton J, Park W, Stolowitz M, Lau K, Yang E, Natarajan A, Ilovich O, Srinivas S, Srinivasan A, Paulmurugan R, Willmann J, Chin FT, Cheng Z, **Iagaru A**, Li F, Gambhir SS. Evaluation of integrin $\alpha_v\beta_6$ cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. *Nat Commun*. 2019 Oct 14;10(1):4673.
86. Park SY, Barrato L, Hatami N, Davidzon G, Gambhir SS, **Iagaru A**. Initial experience with a PET/computed tomography system using silicon photomultiplier detectors. *Nucl Med Commun*. 2019 Nov;40(11):1174-1178.
87. Beinat C, Patel CB, Haywood T, Shen B, Naya L, Gandhi H, Holley D, Khalighi M, **Iagaru A**, Davidzon G, Gambhir SS. Human biodistribution and radiation dosimetry of [^{18}F]DASA-23, a PET probe targeting pyruvate kinase M2. *Eur J Nucl Med Mol Imaging*. 2020 Jan 15. doi: 10.1007/s00259-020-04687-0. Online ahead of print.
88. Sonni I, Minamimoto R, Loening AM, Taviani V, Hatami N, Gambhir SS, Vasanaawala SS, **Iagaru A**. Imaging Patients with Breast and Prostate Cancers Using Combined ^{18}F NaF/ ^{18}F FDG and TOF simultaneous PET/ MRI. *Mol Imaging Biol*. 2020 Apr;22(2):397-406
89. Nobashi T, Zacharias C, Ellis JK, Ferri V, Koran ME, Franc BL, **Iagaru A**, Davidzon GA. Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain ^{18}F -FDG-PET Scans. *J Digit Imaging*. 2020 Apr;33(2):447-455.
90. Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, Davidzon GA, **Iagaru A**. Prospective Evaluation of ^{18}F -DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management. *J Nucl Med*. 2020 Apr;61(4):546-551.
91. Toriihara A, Nobashi T, Baratto L, Duan H, Moradi F, Park S, Hatami N, Aparici CM, Davidzon G, **Iagaru A**. Comparison of 3 Interpretation Criteria for ^{68}Ga -PSMA11 PET Based on Inter- And Intra-reader Agreement. *J Nucl Med*. 2020 Apr;61(4):533-539.
92. Lee JJ, Yang H, Franc BL, **Iagaru A**, Davidzon GA. Deep learning detection of prostate cancer recurrence with ^{18}F -FACBC (fluciclovine, Axumin®) positron emission tomography. *Eur J Nucl Med Mol Imaging*. 2020 Jun 17.
93. Baratto L, Duan H, Ferri V, Khalighi M, **Iagaru A**. The effect of various β values on image quality and semi-quantitative measurements in ^{68}Ga -RM2 and ^{68}Ga -PSMA-11 PET/MRI images reconstructed with a block sequential regularized expectation maximization algorithm. *Clin Nucl Med*. 2020 Jul;45(7):506-513.
94. Nakamoto R, Zaba LC, Rosenberg J, Reddy SA, Nobashi TW, Davidzon G, Aparici CM, Nguyen J, Moradi F, **Iagaru A**, Franc BL. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. *Eur J Nucl Med Mol Imaging*. 2020 Nov;47(12):2787-2795.
95. Natarajan A, Srinivas SM, Azevedo C, Greene L, Bauchet AL, Jouannot E, Lacoste-Bourgeacq AS, Guizon I, Cohen P, Naneix AL, Ilovich O, Cisneros J, Rupanarayan K, Chin FT, **Iagaru A**, Dirbas FM, Karam A, Gambhir SS. Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6

Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy. *Mol Imaging*. 2020 Jan-Dec;19:1536012120939398.

96. Duan H, Khalaf MH, Ferri V, Baratto L, Srinivas SM, Sze DY, **Iagaru A**. High quality imaging and dosimetry for yttrium-90 (⁹⁰Y) liver radioembolization using a SiPM-based PET/CT scanner. *Eur J Nucl Med Mol Imaging*. 2021 Jan 14.
97. Nakamoto R, C Zaba L, Rosenberg J, Arani Reddy S, W Nobashi T, Ferri V, Davidzon G, Mari Aparici C, Nguyen J, Moradi F, **Iagaru A**, Franc BL. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. *Mol Imaging Biol*. 2021 Feb;23(1):139-147.
98. Nakamoto R, Harrison C, Song H, Guja KE, Hatami N, Nguyen J, Moradi F, Franc BL, Mari Aparici C, Davidzon G, **Iagaru A**. Diagnostic Performance of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: An Academic Center Experience Post FDA-Approval. *Mol Imaging Biol*. 2021.

Submitted

1. Duan H, Baratto L, Hatami N, Mari Aparici C, Davidzon G, **Iagaru A**. Dual-Time ⁶⁸Ga-PSMA11 Imaging for Biochemically Recurrent Prostate Cancer Using PMT- and SiPM-Based PET/CT. *Radiology: Imaging Cancer*.
2. Baratto L, Tohiiara1 A, Hatami N, Duan H, Mari Aparici C, Davidzon G, Levin CS, Iagaru A. Results of a Prospective Randomized Trial to Compare 68Ga-DOTA-TATE with SiPM-based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors. *Radiology*.
3. Baratto L, Song H, Duan H, Hatami N, Bagshaw H, Buyyounouski M, Hancock S, Shah S, Srinivas S, Swift P, Moradi F, Davidzon G, **Iagaru A**. PSMA- and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer. *J Nucl Med*.

2. Peer Reviewed Other Journal Articles (Case Reports, Editorials, Invited Commentaries, Appropriate Use Criteria)

1. Jadvar H, Bonyadlou S, **Iagaru A**, Colletti P. ¹⁸F FDG PET/CT Demonstration of Salivary Glands Involvement in Sjogren's Syndrome. *Clin Nucl Med*. 2005 Oct;30(10):698-9.
2. **Iagaru A**, Wassef H, Henderson R. Failed Atrial Septal Defect Repair versus Pulmonary Hypertension with Right Ventricular Failure. *Clin Nucl Med*. 2005 Nov;30(11):767-8.
3. **Iagaru A**, Siegel ME. Demonstration of a Right Inguinal Hernia Containing Urinary Bladder Diverticulum on Whole Body Bone Scan and Pelvic CT. *Eur J Nucl Med Mol Imaging*. 2006 Feb;33(2):234.
4. **Iagaru A**, Mari C, Segall G. ¹⁸F FDG PET Evaluation of Bronchial Plasmacytoma, with CT and MRI Correlation. *Clin Nucl Med*. 2006 May;31(5):279-80.
5. **Iagaru A**, Gamie S, Segall G. ¹⁸F FDG PET Imaging of Urinary Bladder Oat Cell Carcinoma with Widespread Osseous Metastases. *Clin Nucl Med*. 2006 Aug;31(8):476-8.
6. **Iagaru A**, Henderson R. ¹⁸F FDG PET/CT in the Follow-Up of Non-Ossifying Fibroma. *AJR Am J Roentgenol*. 2006. Sep;187(3):830-2.
7. **Iagaru A**, Hachamovitch R, Colletti PM, Wassef H. Ectopic Mediastinal Parathyroid Adenoma on ^{99m}Tc Sestamibi Myocardial Perfusion Scintigraphy. *J Nucl Cardiol*. 2006 Sep;13(5):719-21.
8. **Iagaru A**, McDougall IR. ¹⁸F FDG PET/CT Demonstration of an Adrenal Metastasis in a Patient with Anaplastic Thyroid Cancer. *Clin Nucl Med*. 2007 Jan;32(1):13-5.
9. **Iagaru A**, Mari C, Gambhir SS. Follicular Dendritic Sarcoma within a Focus of Castleman's Disease. Serial ¹⁸F FDG PET/CT in the Follow-Up of Recurrence with Histopathologic Confirmation. *Rev Esp Med Nucl*. 2007 Jan;26(1):40-5.
10. **Iagaru A**, Gamie S, Segall G. ¹⁸F FDG PET Visualization of Urinary Leak Following Nephrostomy Tube Removal. *Clin Nucl Med*. 2007 Feb;32(2):168-169.

11. **Iagaru A**, McDougall IR. Therapy of Thyrotoxicosis. *J Nucl Med*. 2007 Mar;48(3):379-89
12. **Iagaru A**, Quon A. Advances in Metabolic Imaging for Surgical Oncology. *Surg Oncol Clin N Am*. 2007 Apr;16(2):273-92.
13. **Iagaru A**, Chen X, Gambhir SS. Molecular Imaging Can Speed Up Anti-Angiogenic Drug Development. *Nat Clin Pract Oncol*. 2007 Oct;4(10):556-7.
14. Mitra ES, **Iagaru A**, Quon A, Fischbein N. PET Imaging of Skull Base Neoplasms. *PET Clinics*. 2007 Oct;2(4):489-510.
15. **Iagaru A**, Peterson D, Quon A, Dutta S, Twist C, Daghighian F, Gambhir SS, Albanese C. Case study: ¹²³I MIBG Mapping with Intraoperative Gamma Probe for Recurrent Neuroblastoma. *Mol Imaging Biol*. 2008 Jan-Feb;10(1):19-23.
16. **Iagaru A**, Goris ML, Gambhir SS. Perspectives of Molecular Imaging and Radioimmunotherapy in Lymphoma. *Radiol Clin North Am*. 2008 Mar;46(2):243-252.
17. **Iagaru A**, Goris ML. Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on 99mTc-MDP bone scintigraphy confirmed by ¹⁸F FDG PET/CT and bone marrow biopsy. *Eur J Nucl Med Mol Imaging*. 2008 Sep;35(9):1746.
18. Mitra ES, **Iagaru A**. ¹⁸F FDG PET and PET/CT for evaluating primary bone tumors. *PET Clin*. 2010 Jul;5(3):327-40.
19. Mansouri MA, **Iagaru A**. ¹⁸F FDG PET/CT Demonstration of Lymphohistiocytic Meningitis. *Clin Nucl Med*. 2010 Aug;35(8):633-4.
20. Lin F, **Iagaru A**. Current Concepts and Future Directions in Radioimmunotherapy. *Curr Drug Discov Technol*. 2010 Dec 1;7(4):253-62.
21. **Iagaru A**. ¹⁸F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. *Am J Nucl Med Mol Imaging*. 2011;1(1):63-4.
22. Mitra ES, **Iagaru A**, Leung A. Case 166: Metastatic Left Pulmonary Artery Sarcoma. *Radiology*. 2011 Feb;258(2):645-648.
23. McDougall IR, **Iagaru A**. Thyroid Stunning: Fact or Fiction? *Seminars in Nuclear Medicine*. 2011 Mar;41(2):105-112.
24. Mosci C, **Iagaru A**. PET/CT Imaging of Thyroid Cancer. *Clin Nucl Med*. 2011 Dec;36(12):e180-5.
25. Guo H, Mosci C, **Iagaru A**. Demonstration of peripheral nerve root involvement by non-Hodgkin's lymphoma on ¹⁸F FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2012 Apr;39(4):729-30.
26. Mosci C, **Iagaru A**. ¹⁸F NaF PET/CT in the Assessment of Malignant Bone Disease. *PET Clinics*. 2012 Jul;7(3):263-74.
27. Mosci C, McDougall IR, Jeffrey RB, **Iagaru A**. ¹⁸F FDG PET/CT Demonstration of a Liver Metastasis in a Patient with Papillary Thyroid Cancer. *Clin Nucl Med*. 2012 Sep;37(9):e234-6.
28. Delbeke D, Alessio A, **Iagaru A**. Second Sino-American Conference on Nuclear Medicine. *J Nucl Med*. 2013 Apr;54(4):15N-6N.
29. **Iagaru A**, Gambhir SS. Imaging Tumor Angiogenesis: The Road to Clinical Utility. *AJR Am J Roentgenol*. 2013 Aug;201(2):W183-91.
30. Kumar M, **Iagaru A**. ¹⁸F FDG PET/CT Demonstration of Diffuse Lymphohistiocytic Granulomatous Vasculitis. *Clin Nucl Med*. 2013 Aug;38(8):e329-30.
31. Keu KV, **Iagaru A**. The Clinical Use of PET/CT in the Evaluation of Melanoma. *Methods Mol Biol*. 2014;1102:553-80.
32. Jones RP, **Iagaru A**. ¹⁸F NaF Brain Metastasis Uptake in a Patient with Melanoma. *Clin Nucl Med*. 2014 Oct;39(10):e448-50.
33. Mahapatra S, Chin CC, **Iagaru A**, Heerema-McKenney A, Twist CJ. Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation. *Pediatr Blood Cancer*. 2014 Nov;61(11):2107-9.
34. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, **Iagaru A**, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. *J Natl Compr Canc Netw*. 2014 Dec;12(12):1671-80.

35. Jackson T, Sabbah N, **Iagaru A**. ^{123}I Accumulation in Thoracic Neoesophagus Masking Residual Papillary Thyroid Cancer. *Clin Nucl Med*. 2015 Feb;40(2):e150-1.
36. Harolds JA, Oates ME, Guiberteau MJ, Ghesani M, Scanlon MH, **Iagaru A**. New training pathways to dual certification in nuclear medicine and radiology. *J Nucl Med*. 2015 Jun;56(6):17N-18N.
37. Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, **Iagaru A**, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. *J Natl Compr Canc Netw*. 2015 Sep;13(9):1140-50.
38. **Iagaru A**. ^{18}F -Fluoride PET in the Assessment of Malignant Bone Disease. *J Nucl Med*. 2015 Oct;56(10):1476-7.
39. Sonni I, **Iagaru A**. PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies. *PET Clin*. 2016 Jul;11(3):261-72.
40. **Iagaru A**, Mittra E, Colletti PM, Jadvar H. Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. *J Nucl Med*. 2016 Oct;57(Suppl 3):19S-24S.
41. Mansi R, Minamimoto R, Mäcke H, **Iagaru A**. Bombesin-Targeted PET of Prostate Cancer. *J Nucl Med*. 2016 Oct;57(Suppl 3):67S-72S.
42. Sonni I, Baratto L, **Iagaru A**. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin. *PET Clin*. 2017 Apr;12(2):159-171.
43. Subramaniam RM, Jadvar H, Colletti PM, Guimaraes A, Gullapali R, **Iagaru A**, McConathy J, Meltzer CC, Nadel H, Noto RB, Packard AB, Rohren EM, Oates ME. ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. *J Nucl Med*. 2017 Jul;58(7):1174-1176
44. **Iagaru A**. Dual-Integrin $\alpha_3\beta_3$ - and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer (^{68}Ga -BBN-RGD). *J Nucl Med*. 2017 Oct;58(10):1706.
45. Gerson JN, Witteles RM, Chang DT, Beygui RE, **Iagaru A**, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. *Pancreas*. 2017 Nov/Dec;46(10):1381-1385.
46. Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, **Iagaru A**, Nadel H, Quinn DI, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L. Appropriate Use Criteria for ^{18}F -FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. *J Nucl Med*. 2017 Dec;58(12):2026-2037.
47. **Iagaru A**. Will GRPR Compete with PSMA as a Target in Prostate Cancer? *J Nucl Med*. 2017 Dec;58(12):1883-1884.
48. Yurkiewicz IR, Ganjoo KN, **Iagaru A**. Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on ^{18}F -FDG PET/CT. *Clin Nucl Med*. 2018 Apr;43(4):e113-e114.
49. Bradley K, McGowan DR, Gleeson FV, Johnson GB, Young JR, Levin CS, Davidzon GA, **Iagaru A**. Embrace Progress. *J Nucl Med*. 2018 Jul;59(7):1169.
50. **Iagaru A**, Minamimoto R. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. *PET Clin*. 2018 Jul;13(3):383-393.
51. Baratto L, Jadvar H, **Iagaru A**. Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. *Mol Imaging Biol*. 2018 Aug;20(4):501-509.
52. Bartelink IH, Jones EF, Shahidi-Latham SK, Rong ELP, Zheng Y, Vicini P, van 't Veer L, Wolf D, **Iagaru A**, Kroetz DL, Prideaux B, Cilliers C, Thurber G, Wimana Z, Gebhart G. Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. *Clin Pharmacol Ther*. 2019 Jul;106(1):148-163.
53. Laudicella R, Davidzon G, Vasanawala S, Baldari S, **Iagaru A**. ^{18}F -FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. *Nucl Med Mol Imaging*. 2019 Aug;53(4):296-299.
54. Wangerin KA, **Iagaru A**. Improved Scatter Correction to Eliminate Halo-Artifacts for ^{68}Ga -labeled Radiopharmaceuticals in PET Imaging. *J Nucl Med*. 2019 Sep;60(9):1334.
55. Wangerin KA, **Iagaru A**. ^{68}Ga Scatter Correction to Eliminate Halo-Artifacts in PET Imaging. *Urology*. 2019 Sep;131:262.
56. Hope TA, Fayad ZA, Fowler KJ, Holley D, **Iagaru A**, McMillan AB, Veit-Haiback P, Witte RJ, Zaharchuk G, Catana C. Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations. *J Nucl Med*. 2019 Oct;60(10):1340-1346.

57. Girod BJ, Guja KE, Davidzon G, Chan F, Zucker E, Franc BL, Moradi F, **Iagaru A**, Aparici CM. Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation. *Radiol Case Rep*. 2019 Nov 19;15(2):117-119.
58. Duan H, Baratto L, **Iagaru A**. The Role of PET/CT in the Imaging of Pancreatic Neoplasms. *Semin Ultrasound CT MR*. 2019 Dec;40(6):500-508.
59. Laudicella R, Baratto L, Minutoli F, Baldari S, **Iagaru A**. Malignant Cutaneous Melanoma: Updates in PET Imaging. *Curr Radiopharm*. 2020;13(1):14-23.
60. Seib CD, Chen J, **Iagaru A**. Shifting Trends and Informed Decision-Making in the Management of Graves' Disease. *Thyroid*. 2020 Mar;30(3):351-354.
61. Maurer AH, Abell T, Bennett P, Diaz JR, Harris LA, Hasler W, **Iagaru A**, Koch KL, McCallum RW, Parkman HP, Rao SSC, Tulchinsky M. Appropriate Use Criteria for Gastrointestinal Transit Scintigraphy. *J Nucl Med*. 2020 Mar;61(3):11N-17N.
62. Sonni I, Minamimoto R, Baratto L, **Iagaru A**. Response to: Letter to the Editors: Re: Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na^[18F] F and [^{18F}]FDG: a Focus on Skeletal Lesions. *Mol Imaging Biol*. 2020 Apr;22(2):221-222.
63. Baratto L, Duan H, Maecke HR, **Iagaru A**. Imaging the Distribution of Gastrin Releasing Peptide Receptors in Cancer. *J Nucl Med*. 2020 Jun;61(6):792-798.
64. Kozlov A, Pantel A, **Iagaru A**, Ikeda D. Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging ¹⁸F-FDG PET/CT in a Woman with a Normal Screening Mammogram. *Clin Lung Cancer*. 2020 Jun 19:S1525-7304(20)30206-0.
65. Weinreb J, Choyke P, **Iagaru A**, Ippolito J, Lockhart M, Merrick G, Sachdev S, Silva E 3rd, Taneja SS, Tempany C, Wahl R, Rosenkrantz A. ACR Stakeholder Prostate Summit. *J Am Coll Radiol*. 2020 Aug;17(8):1068-1070.
66. Moradi F, **Iagaru A**. The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer. *Semin Nucl Med*. 2020 Sep;50(5):434-446.
67. Ceci F, Castellucci P, Polverari G, **Iagaru A**. Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. *Curr Opin Urol*. 2020 Sep;30(5):641-648.
68. Guja KE, Brown R, Girod B, Song H, Harrison C, Franc BL, Moradi F, Davidzon G, **Iagaru A**, Aparici CM. An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on ¹⁸F FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2020 Sep 12.
69. Franc BL, **Iagaru A**. Letter to the Editor: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center". *J Nucl Med*. 2020 Oct 30:jnumed.120.258160.
70. Li D, Patel CB, Xu G, **Iagaru A**, Zhu Z, Zhang L, Cheng Z. Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging. *Front Immunol*. 2020 Oct 30;11:592389.
71. Czernin J, **Iagaru A**. Humana and ¹⁸F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. *J Nucl Med*. 2020 Nov 13.
72. Moradi F, **Iagaru A**. Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast! *AJR Am J Roentgenol*. 2020 Dec 23:1-2.

3. Non-Peer Reviewed Journal Articles

1. Mittra E, **Iagaru A**. Novel techniques in breast imaging. *US Radiology*. 2008 1(1):47-5.
2. Lin FI, **Iagaru A**. Updates on PET/CT and Thyroid Cancer. *Applied Radiology*. 2010 39(12):8-12.

4. Book Chapters

1. **Iagaru A**. Nuclear Medicine. In: Uzelac A, Davis R, eds. *Blueprints Radiology*, 2nd Edition. Lippincott Williams & Wilkins, Nov 2005.
2. **Iagaru A**, McDougall IR. Thyroid Imaging: Nuclear Medicine Techniques. In: Wass J, Shalet S, eds. *Oxford Textbook of Endocrinology and Diabetes*, 2nd Edition. Oxford University Press

3. Keu KV, **Iagaru A**. The Pre-Clinical and Clinical Use of PET/CT in the Evaluation of Melanoma. In: Thurin M, Marincola F, eds. *Molecular Diagnostics for Melanoma*. Humana Press.
4. **Iagaru A**, McDougall IR. PET/CT in Lymphoma of the Thyroid. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2nd Edition. Humana Press.
5. **Iagaru A**, McDougall IR. PET/CT in Follicular Cancer Including Hürthle Cell Cancer. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2nd Edition. Humana Press.
6. **Iagaru A**, McDougall IR. PET/CT in Anaplastic Cancer of the Thyroid. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2nd Edition. Humana Press.
7. **Iagaru A**, McDougall IR. PET/CT in Medullary Thyroid Cancer. In: Wartofsky L, Van Nostrand D, eds. *Thyroid Cancer: a Comprehensive Guide to Clinical Management*, 2nd Edition. Humana Press.
8. Sonni I, Garibotto V, Das D, **Iagaru A**, Tarik F. Massoud. PET/MRI in Brain Tumors. In: **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology*. Springer.
9. Sonni I, Baratto L, Freitag MT, Giesel F, Eiber M, **Iagaru A**. PET/MRI in Prostate Cancer. In: **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology*. Springer.
10. Minamimoto R, Taviani V, Vasanawala S, **Iagaru A**. Whole-body PET/MRI Applications in Oncology. In: **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology*. Springer.
11. Jurcic GC, Wong JYC, Knox SJ, Wahl DR, Rosenblat TL, Baratto L, **Iagaru A**, Meredith RF, Ha CS. Targeted Radionuclide Therapy. In Tepper J, ed. *Clinical Radiation Oncology*, Elsevier.

5. Books

1. **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology*. Springer (2018).

6. Presentations

Invited Presentations

1. ¹⁸F FDG PET/CT in the Management of Ovarian Carcinoma. PAVAHCS PET/CT Symposium, Palo Alto, CA. Mar 24, 2007.
2. ¹⁸F FDG PET/CT Assessment of Patients with Thyroid Cancer. PAVAHCS PET/CT Symposium, Palo Alto, CA. Mar 24, 2007.
3. Radiation Therapy Planning for GI Cancers: When Can ¹⁸F FDG PET/CT Evaluation Provide Useful Information? RSNA Annual Meeting, Chicago, IL. Nov 28, 2007.
4. Sarcomas: Classification, Diagnosis and Therapeutic Approaches, with an Emphasis on the Role of ¹⁸F FDG PET/CT. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 28, 2008.
5. ¹⁸F Sodium Fluoride: An Unfinished Business. MIPS Seminar Series, Stanford, CA. Nov 17, 2008.
6. Old Tracers, New Ideas: Clinical Research in Nuclear Medicine. Nuclear Medicine Grand Rounds. Stanford, CA. Nov 18, 2008.
7. The Physiology of ¹⁸F FDG and Principles of PET Scanning. 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 12, 2009.
8. Vascular Tracer Activity: Disease or Not? 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2009.

9. PET/CT as an Adjunctive Test for Infectious or Inflammatory Disease? 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2009.
10. Bexxar® and Zevalin® Radioimmunotherapy in Non-Hodgkin Lymphomas. Stanford Nuclear Medicine Stampede, Stanford, CA. Mar 21, 2009.
11. Novel Strategies for PET/CT Imaging in Oncology. Medical Oncology Grand Rounds. Stanford, CA. Nov 10, 2009.
12. Updates on PET/CT and Thyroid Cancer. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 11, 2010.
13. ^{99m}Tc-MDP Scintigraphy vs. ¹⁸F NaF PET/CT vs. ¹⁸F FDG PET/CT for Detection of Skeletal Metastases. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 12, 2010.
14. Whole Body MRI vs. PET: Is PET Still Best for Oncology? 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2010.
15. An Integrated Approach for the Early Detection of Cancer. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2010.
16. Updates on PET/CT and Thyroid Cancer. Nuclear Medicine Grand Rounds. Stanford, CA. Apr 6, 2010.
17. Introduction to PET/CT. Hospital Mae de Deus Symposium, Porto Alegre, Brazil. Apr 26, 2010.
18. Lymphomas: What Can Nuclear Medicine Do for You? Medical Oncology Grand Rounds. Stanford, CA. Nov 16, 2010.
19. Imaging Angiogenesis: What Can Different Modalities Do? PET/CT in Angiogenesis Imaging. RSNA Annual Meeting, Chicago, IL. Dec 2, 2010.
20. ¹⁸F FPPRGD₂: A Novel PET Radiopharmaceutical for Imaging Breast Cancer. Breast Disease Management Group Grand Rounds. Stanford, CA. Apr 1, 2011.
21. Bexxar® and Zevalin® Radioimmunotherapy in Non-Hodgkin Lymphomas: Clinical Results. SNM Annual Meeting, San Antonio, TX. Jun 4, 2011.
22. Practical Considerations and Clinical Applications of Radioimmunotherapy. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 23, 2012.
23. Beyond FDG: Novel Clinical PET Radiopharmaceuticals. 17th Nuclear Medicine Annual Meeting, Coimbra, Portugal. Apr 25, 2012.
24. Novel PET Tracers and Their Future Use in Assessment of Response to Treatment. ASCO Annual Meeting, Chicago, IL. Jun 1-5, 2012 (Session Organizer and Co-Chair).
25. SPECT/CT in Thyroid and Parathyroid Diseases. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012 (Session Organizer and Moderator).
26. ¹⁸F NaF PET/CT and ¹⁸F FDG PET/CT: What is Their Role in the Management of Bone Malignancy? SNM Annual Meeting, Miami, FL. Jun 9-13, 2012 (Session Organizer and Moderator).
27. Thyroid Imaging and Therapy for the Lay Person. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
28. Molecular Imaging in the Assessment and Follow-Up of Breast Cancer. Society of Nuclear Medicine of Puerto Rico Annual Meeting, Rio Grande, PR. Oct 12-14, 2012.
29. ¹⁸F NaF PET/CT and ¹⁸F FDG PET/CT: What is Their Role in the Management of Bone Malignancy? Society of Nuclear Medicine of Puerto Rico Annual Meeting, Rio Grande, PR. Oct 12-14, 2012.
30. Society of Nuclear Medicine & Molecular Imaging and Chinese Society of Nuclear Medicine 2nd Sino-American Conference, New Orleans, LA. Jan 23-27, 2013 (Organizer and Co-Chair).

31. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 28, 2013.
32. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. American Urological Association Annual Meeting, San Diego, CA. May 4-8, 2013. (Plenary Session)
33. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. Medical Oncology Grand Rounds. Stanford, CA. May 14, 2013.
34. Update of Nuclear Medicine Imaging of Prostate Cancer. Urology Grand Rounds. Stanford, CA. Jun 4, 2013.
35. PET/CT in Clinical Practice: Evidence-based Use and Appropriateness Criteria. ASCO Annual Meeting, Chicago, IL. May 31 - Jun 4, 2013 (Session Organizer and Co-Chair; Speaker).
36. Molecular Imaging in Breast Cancer - Present and Future. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013 (Session Organizer and Moderator; Speaker).
37. ^{18}F NaF PET/CT in the Evaluation of Skeletal Malignancy (Primary and Metastatic Disease). SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013 (Session Organizer and Moderator; Speaker).
38. PET/CT Imaging of Angiogenesis. Stanford University and Peking University Joint Symposium, Beijing. Apr 15, 2014 (Organizer; Speaker).
39. From Time-of-Flight PET/CT to Time-of-Flight PET/MRI: Stanford Experience. Chinese Society of Nuclear Medicine and CFMA Spring Meeting, Shenzhen, China. Apr 17-20, 2014 (Keynote Speaker).
40. PET/MRI: The Next Stop for Imaging Angiogenesis in Brain and Breast Cancers. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014 (Session Organizer; Speaker).
41. Bone Scintigraphy in the Management of Patients with Metastatic Castrate-Resistant Prostate Cancer. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014 (Session Organizer and Moderator; Speaker).
42. Differentiating Benign from Malignant Bone Disease: The Role of PET/CT. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
43. Imaging Angiogenesis with PET: Radiopharmaceuticals, Opportunities, and Controversies. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
44. Clinical Translation of PET/MRI: Stanford Experience. Stanford University and Peking Union Medical College Joint Symposium, Beijing. Sep 14, 2014.
45. PET Imaging: From Bench to Bedside. St. Mary - Catholic University Molecular Imaging Symposium, Seoul, Korea. Sep 16, 2014.
46. Site Readiness and Challenges for Large Clinical Trials. WMIS Annual Congress, Seoul, Korea. Sep 17-20, 2014.
47. From PET/CT to PET/MRI: Initial Experience with SUV Measurements Using the First TOF Simultaneous PET/MRI Scanner. EANM Annual Congress, Stockholm, Sweden. Oct 18-22, 2014.
48. From PET/CT to PET/MRI: Initial Experience with SUV Measurements Using the First TOF Simultaneous PET/MRI Scanner. WRSNM Annual Meeting, Seattle, WA. Oct 30 - Nov 2, 2014.
49. Clinical PET Innovations: Simultaneous TOF PET/MR and Fully-convergent PET reconstruction. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.
50. ^{18}F NaF: 2015 Updates. SNMMI Mid-Winter Meeting, San Antonio, TX. Jan 22-25, 2015.
51. Current Status of ^{18}F NaF PET/CT. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 21-22, 2015.

52. PET/MRI Case Review. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 21-22, 2015.
53. PET/MRI Future Directions: Oncology. ISMRM&SNMMI Joint Symposium at the SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015 (Session Organizer and Moderator; Speaker).
54. PET Imaging for Prostate Cancer in the United States: Beyond ^{18}F FDG and ^{18}F NaF. WRSNM Annual Meeting, Monterey, CA. Oct 22-25, 2015.
55. Advanced Molecular Imaging and PET: A New Era of Personalized and Precision Medicine. Japanese Society of Nuclear Medicine Annual Meeting, Tokyo, Japan. Nov 5-7, 2015.
56. From PET/CT to PET/MRI: Initial Clinical Experience at Stanford. Japanese Society of Nuclear Medicine Annual Meeting, Tokyo, Japan. Nov 5-7, 2015.
57. PET/MRI at Stanford: Initial Clinical Experience and Future Directions. Peking Union Medical College International Forum on Frontier Technology, Beijing, China. Nov 15, 2015.
58. Anti-Angiogenesis Treatment: Can PET Predict Response Early and Accurately? SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.
59. ^{18}F NaF PET in Prostate Cancer: 2016 Updates. High Country Nuclear Medicine Annual Conference, Vail, CO. Feb 27 - Mar 2, 2016.
60. How to Get Away with PET+MRI. 4th Theranostics World Congress, Melbourne, Australia. Nov 7-9, 2016.
61. Imaging the Expression of Gastrin Releasing Peptide Receptors in Prostate Cancer Using Ga-68 Labeled Antagonists. 4th Theranostics World Congress, Melbourne, Australia. Nov 7-9, 2016.
62. The Current Status of PET+MRI in the United States, Its Future Outlook and What to be Expected. Osaka Advanced Imaging Medical Research Group Annual Meeting, Osaka, Japan. Feb 18-19, 2017.
63. Oncological PET+MRI in the United States. Advanced Imaging Symposium, Shenyang, China. May 6, 2017.
64. PET Imaging of Cardiac Sarcoidosis: Current Status and Future Directions. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
65. SPECT/CT in Endocrinology. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
66. Updates in Molecular Imaging of Prostate Cancer: Newly Approved and Promising PET Radiopharmaceuticals. Western Regional SNMMI Annual Meeting, Vancouver, BC. Nov 3-5, 2017.
67. Current Status and Future Trends for Future Use of PET+MRI in the United States. Western Regional SNMMI Annual Meeting, Vancouver, BC. Nov 3-5, 2017.
68. PSMA and GRPR Ligands as New and Emerging Prostate Cancer Imaging Agents and Theranostics. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.
69. How to Read: ^{68}Ga -DOTA-TATE PET Scan. Northern California SNMMI Annual Meeting. Feb 22, 2018.
70. Creating Probes for Theranostics. World Federation of Nuclear Medicine and Biology. Apr 23, 2018 (Plenary Session).
71. Imaging in Prostate Cancer. Stanford Cancer Institute Urologic Oncology. May 16, 2018.
72. State-of-the-Art Lecture: Molecular Imaging in GU Malignancies. American Urological Association Annual Meeting. May 21, 2018.

73. PET Imaging and Theranostics in Prostate Cancer. Stanford Urology Grand Rounds. Jun 5, 2018.
74. Non-PSMA Prostate Cancer Theranostics. SNMMI Annual Meeting, Philadelphia, PA. Jun 23, 2018.
75. ⁶⁸Gallium Imaging and Related Theranostics: Experience From a Center in the United States. SNMMI Annual Meeting, Philadelphia, PA. Jun 26, 2018.
76. Nuclear Techniques in Infiltrative Diseases: Amyloid and Sarcoid Imaging. ASNC Annual Meeting, San Francisco, CA. Sep 9, 2018.
77. Molecular Imaging and Theranostics in Oncology: Learning from Failures and Advancing Patient Care. UAB Molecular Imaging Symposium, Birmingham, AL. Oct 24, 2018.
78. Novel PET Imaging in Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Nov 27, 2018.
79. Molecular Imaging and Theragnostics in Oncology: Learning from Challenges and Delivering on Promises. NIH, Bethesda, MD. Dec 10, 2018.
80. Prostate Cancer: Molecular Imaging Updates. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 9, 2019.
81. Gastrin-Releasing Peptide Receptors for Theranostics in Prostate Cancer. Theranostics World Congress, Jeju, South Korea. Mar 2, 2019.
82. Novel Imaging and Treatments in Neuroendocrine Tumors. ASTRO Multidisciplinary Thoracic Cancers Symposium, San Diego, CA. Mar 15, 2019.
83. How to Get Away with PET+MRI. University of Maryland Radiology Grand Rounds, Baltimore, MD. Mar 27, 2019.
84. Next generation of SSTR imaging. NANETS Multidisciplinary NET Medical Symposium, Boston, MA. Oct 3-5, 2019.
85. Current Landscape of Diagnostic Molecular Imaging of Prostate Cancer in the United States. AdMeTech Annual Global Summit on Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA. Oct 3-5, 2019.
86. Neuroendocrine Theragnostics. 2019 Western Region SNM Annual Meeting, Tucson, AZ. November 1-3, 2019.
87. Landscape of New and Future PET Tracers for Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019
88. Gastrin Releasing Peptide Receptors: When in the Course of Prostate Cancer Will They Be Useful? RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.
89. Fluciclovine/PSMA Cases. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.
90. Research PET Radiopharmaceuticals in Prostate Cancer: PSMA and Beyond. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 8, 2020.
91. GRPR Theragnostics. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.

Other Presentations (selected)

1. **Iagaru A**, Kundu R, Jadvar H, Nagle D. Does ¹⁸F FDG PET Change the Staging or Surgical Management of Anal Carcinoma? ACNP Annual Meeting, San Diego, CA. Jan 16-19, 2005.

2. **Iagaru A.** PET/CT Challenges. Conjoint Southern Pacific Society of Nuclear Medicine and Los Angeles Radiological Society Spring Meeting, Los Angeles, CA. May 14, 2005.
3. **Iagaru A,** Chawla SP, Menendez LR, Conti PS. The Role of ^{18}F FDG PET and CT in Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. SNM Annual Meeting, Toronto, Canada. Jun 18-22, 2005.
4. **Iagaru A,** Masamed R, Singer PA, Conti PS. Detection of Occult Medullary Thyroid Cancer with ^{18}F FDG PET and PET/CT. RSNA Annual Meeting, Chicago, IL. Nov 27 - Dec 2, 2005.
5. **Iagaru A,** Quon A, Goris ML, McDougall IR, Gambhir SS. Merkel Cell Carcinoma: Is There a Role for ^{18}F FDG PET/CT? AMI Annual Conference, Orlando, FL. Mar 25-29, 2006.
6. **Iagaru A,** Quon A, Ikeda D, Daniel B, Goris ML, McDougall IR, Gambhir SS. Comparison of Mammography, Breast MRI and ^{18}F FDG PET/CT for Breast Cancer Detection. AMI Annual Conference, Orlando, FL. Mar 25-29, 2006.
7. **Iagaru A,** Masamed R, Silberman H, Keesara S, Conti PS. The Role of ^{18}F FDG PET/CT and Breast MRI in the Management of Breast Cancer. ASCO Annual Meeting, Atlanta, GA. Jun 2-6, 2006.
8. **Iagaru A,** Quon A, Ikeda D, Daniel B, Goris ML, McDougall IR, Gambhir SS. ^{18}F FDG PET/CT, Breast MRI and Mammography: Can Breast Cancer Be Reliably Detected? SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
9. **Iagaru A,** Masamed R, Sankhala KK, Chawla S, Menendez L, Fedenko A, Conti PS. Post-Ifosfamide Therapy Inflammation in Musculoskeletal and Soft-Tissue Sarcomas: Evaluation with ^{18}F FDG PET and PET/CT. SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
10. **Iagaru A,** Masamed R, Quan V, Singer PA, Conti PS. Detection of Occult Papillary Thyroid Cancer with ^{18}F FDG PET/CT. SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
11. **Iagaru A,** Quon A, Johnson D, Goris ML, McDougall IR, Gambhir SS. ^{18}F FDG PET/CT in the Management of Melanoma. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2006.
12. **Iagaru A,** Quon A, Goris ML, Gambhir SS, McDougall IR. ^{18}F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2006.
13. **Iagaru A,** Quan V, Jadvar H, Conti PS. Sentinel Lymph Node Scintigraphy and ^{18}F FDG PET/CT in the Management of Breast Cancer. ACNP Annual Meeting, San Antonio, Tx. Feb 15-18, 2007.
14. **Iagaru A,** Wang Y, Mari C, Rodriguez CA, Quon A, Goris ML, Gambhir SS. ^{18}F FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan? ACNP Annual Meeting, San Antonio, Tx. Feb 15-18, 2007.
15. **Iagaru A,** Mitra E, Kaplan MJ, Quon A, Gambhir SS. ^{18}F FDG PET/CT in Squamous Cell Carcinoma of the Head and Neck: What is the Definition of Whole-Body Scanning? SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
16. **Iagaru A,** Mitra E, Quon A, Gambhir SS, McDougall IR. ^{18}F FDG PET/CT Evaluation of Ovarian Cancer. SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
17. **Iagaru A,** Zhu H, Mari C, Knox SJ, Goris ML. ^{90}Y -Ibritumomab (Zevalin[®]) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
18. **Iagaru A,** Zhu H, Mari C, Knox SJ, Ganjoo K, Goris ML. Comparison of Efficacy and Toxicity of Bexxar and Zevalin in the Management of Refractory Non-Hodgkin's Lymphoma. EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
19. **Iagaru A,** McDougall IR. ^{18}F FDG PET/CT in the Management of Papillary Thyroid Cancer, with an Emphasis on Thyroglobulin, TSH and Lesion SUVmax Values. EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
20. **Iagaru A,** Quon A, Jacobs C, Marina N, McDougall IR, Gambhir SS. Osseous and soft tissue sarcomas: when can ^{18}F FDG PET/CT evaluation provide useful information? EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.

21. **Iagaru A**, Rodriguez CA, El-Maghraby T, Quon A, Gambhir SS, McDougall IR. ¹⁸F FDG PET/CT Evaluation of Patients with Cervical Cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
22. **Iagaru A**, Mitra E, Le Q, Quon A, Gambhir SS. ¹⁸F FDG PET/CT in Nasopharyngeal Carcinoma: What Do We Need to Scan? RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
23. **Iagaru A**, Mitra E, Quon A, Daniel B, Ikeda D, Herfkens R, McDougall IR, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Patients with Breast Cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
24. **Iagaru A**, Zhu H, Mari C, Knox SJ, Ganjoo K, Goris ML. ¹³¹I-Tositumomab (Bexxar[®]) vs. ⁹⁰Y-Ibritumomab (Zevalin[®]) in Refractory/Relapsed Non-Hodgkin's Lymphoma. ACNP Annual Meeting, Newport Beach, CA. Feb 14-17, 2008.
25. **Iagaru A**, Mitra E, Quon A, Gambhir SS. ¹⁸F FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning? ACNP Annual Meeting, Newport Beach, CA. Feb 14-17, 2008.
26. **Iagaru A**. Sarcomas: Classification, Diagnosis, and Therapeutic Approaches with an Emphasis on the Role of ¹⁸F FDG PET/CT. Northern California Chapter SNM Annual Meeting, Pleasanton, CA. Feb 28, 2008.
27. **Iagaru A**, Mitra ES, Gambhir SS, Goris ML. Can ¹¹¹In-Ibritumomab Imaging Predict the Outcome of ⁹⁰Y-Ibritumomab (Zevalin[®]) Therapy in Refractory Non-Hodgkin's Lymphoma (NHL)? SNM Annual Meeting, New Orleans, LA. Jun 14-18, 2008.
28. Mitra ES, Quon A, McDougall IR, Gambhir SS, **Iagaru A**. ¹⁸F-FDG PET/CT in the Evaluation of Pediatric Sarcomas. SNM Annual Meeting, New Orleans, LA. Jun 14-18, 2008.
29. **Iagaru A**, Knox SJ, Goris ML. ¹³¹I-Tositumomab (Bexxar[®]) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. EANM Annual Congress, Munich, Germany. Oct 11-15, 2008.
30. **Iagaru A**, Mitra ES, Quon A, Jacobs C, Marina N, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas: Differences between Adult and Pediatric Patients. EANM Annual Congress, Munich, Germany. Oct 11-15, 2008.
31. **Iagaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. A Novel Strategy for a Cocktail ¹⁸F Fluoride and ¹⁸F FDG PET/CT Scan for Evaluation of Malignancy. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.
32. **Iagaru A**, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Response to Oncolytic Herpes Simplex Virus (NV 1020) Therapy in Patients with Colorectal Cancer Metastatic to the Liver. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.
33. **Iagaru A**, Knox SJ, Goris ML. ¹³¹I-Tositumomab (Bexxar[®]) vs. ⁹⁰Y-Ibritumomab (Zevalin[®]) in Refractory/Relapsed Non-Hodgkin's Lymphoma: Clinical Experience. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.
34. **Iagaru A**, Mitra ES, Dick, DW, Quon A, Gambhir SS. Prospective Evaluation of ^{99m}Tc-MDP Scintigraphy, ¹⁸F NaF PET/CT and ¹⁸F FDG PET/CT for Detection of Skeletal Metastases. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.
35. **Iagaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. Cocktail ¹⁸F Fluoride and ¹⁸F FDG PET/CT Scan for Evaluation of Malignancy. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.
36. Mitra ES, Quon A, Gambhir SS, **Iagaru A**. Efficacy of ¹⁸F-FDG PET/CT for Breast Cancer. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.
37. **Iagaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. Cocktail ¹⁸F Fluoride and ¹⁸F FDG PET/CT Scan for Evaluation of Malignancy. WRSNM Annual Meeting, Monterey, CA. Oct 29-Nov 1, 2009.
38. **Iagaru A**, Young P, Mitra ES, Quon A, Dick DW, Gambhir SS, Herfkens R. Prospective Evaluation of ^{99m}Tc-MDP Scintigraphy, ¹⁸F NaF PET/CT, ¹⁸F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. RSNA Annual Meeting, Chicago, IL. Nov 29-Dec 4, 2009.

39. **Iagaru A**, Mitra ES, Dick DW, Goris ML, Gambhir SS. Combined ^{18}F NaF and ^{18}F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study. ACNM/SNM Mid-Winter Meeting, Albuquerque, NM. Jan 27-29, 2010.
40. **Iagaru A**, Mitra ES, Dick DW, Gambhir SS. Combined ^{18}F NaF and ^{18}F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study. EANM Annual Congress, Vienna, Austria. Oct 9-13, 2010.
41. **Iagaru A**, Maeda LS, Lin FI, Hoppe RT, Rosenberg SA, Gambhir SS, Advani RH. Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for ^{18}F FDG PET/CT Surveillance? EANM Annual Congress, Vienna, Austria. Oct 9-13, 2010.
42. Lin IF, Rao JE, Mitra ES, Gambhir SS, **Iagaru A**. Prospective Comparison of Combined ^{18}F FDG and ^{18}F NaF vs. Conventional ^{18}F FDG PET/CT Imaging for Detection of Malignancy. RSNA Annual Meeting, Chicago, IL. Nov 27-Dec 2, 2010.
43. **Iagaru A**, Maeda LS, Lin FI, Hoppe RT, Rosenberg SA, Gambhir SS, Advani RH. Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for ^{18}F FDG PET/CT Surveillance? ACNM/SNM Mid-Winter Meeting, Palm Springs, CA. Jan 20-23, 2011.
44. Nguyen JQ, Davis K, Mitra ES, Quon A, Gambhir SS, Marina N, **Iagaru A**. Comparison of Clinical Utility of ^{18}F FDG PET/CT and $^{99\text{m}}\text{Tc}$ MDP Bone Scintigraphy in Patients with Ewing's Sarcoma and Other Forms of Sarcomas. ACNM/SNM Mid-Winter Meeting, Palm Springs, CA. Jan 20-23, 2011.
45. **Iagaru A**, Mitra ES, Sathekge M, Prakash V, Iyer V, Dick D, Lapa P, Isidoro J, de Lima J, Gambhir SS. Combined ^{18}F NaF and ^{18}F FDG PET/CT: Initial Results of a Multi-Center Trial. SNM Annual Meeting, San Antonio, TX. Jun 4-8, 2011.
46. **Iagaru A**, Mosci C, Mitra ES, Shen B, Chin F, Chen X, Telli M, Gambhir SS. ^{18}F FPPRGD₂ in Breast Cancer Subjects: A Novel PET Radiopharmaceutical for Imaging $\alpha_v\beta_3$ Integrin Levels. SNM Annual Meeting, San Antonio, TX. Jun 4-8, 2011.
47. Nguyen JQ, Davis K, Mitra ES, Gambhir SS, Marina N, **Iagaru A**. Clinical Utility of ^{18}F FDG PET/CT and $^{99\text{m}}\text{Tc}$ MDP Bone Scintigraphy in Patients with Ewings Sarcoma and Other Sarcomas. RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.
48. Takehana C, Twist C, Mitra E, Quon A, Gambhir SS, **Iagaru A**. Post-Transplant Lymphoproliferative Disorder: Is There a Role for ^{18}F FDG PET/CT? RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.
49. Sampath SC, Sampath SC, Lutz AM, Willmann JK, Mitra ES, Gambhir SS, **Iagaru A**. The Value of Combined ^{18}F NaF and ^{18}F FDG PET/CT Versus CT Alone for Evaluation of Osseous Malignancy. RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.
50. Mosci C, Akatsu H, Basina M, Dosiou C, **Iagaru A**. The role of diagnostic ^{123}I whole body scan prior to ablation of thyroid remnant in patients with papillary thyroid cancer. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
51. Davidzon G, Wakelee H, Neal J, Mitra ES, Quon A, **Iagaru A**. Utility of ^{18}F FDG PET/CT in patients with advanced thymic neoplasms. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
52. Sampath SC, Sampath SC, Lutz A, Willmann JK, Mitra ES, Gambhir SS, **Iagaru A**. Evaluation of NaF PET/CT, FDG PET/CT, combined NaF/FDG PET/CT and CT alone for detection of bone metastases. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
53. Takehana C, Mitra ES, Quon A, Gambhir SS, **Iagaru A**. ^{18}F FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
54. **Iagaru A**, Mosci C, Mitra ES, Shen B, Chin F, Fischbein N, Gambhir SS. ^{18}F FPPRGD₂ in GBM: Imaging $\alpha_v\beta_3$ integrin levels as a biomarker of disease recurrence. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
55. Keu KV, Mitra ES, Quon A, **Iagaru A**. Metabolic Imaging Patterns of Complete Local Response to Chemoradiation in Patients with Nasopharyngeal Carcinoma: A Review. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.

56. Keu KV, Nair VS, Mittra ES, Quon A, Gambhir SS, **Iagaru A**. The Impact of Partial Volume Correction in the Evaluation of Solitary Pulmonary Nodules by FDG PET/CT in a Population at Intermediate Risk of Lung Cancer. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
57. Keu KV, Mittra ES, Quon A, Gambhir SS, **Iagaru A**. Feasibility of Limited Thoracic FDG PET/CT for the Evaluation of Solitary Pulmonary Nodules in Patients With Intermediate and High Risk of Lung Cancer. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
58. **Iagaru A**, Mosci C, Mittra ES, Shin B, Chin F, Gambhir SS. $\alpha_v\beta_3$ Integrins as a Biomarker of Disease Recurrence in Glioblastoma Multiforme: Initial Clinical Results Using ^{18}F FPPRGD₂ PET/CT. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
59. **Iagaru A**, Mosci C, Akatsu H, Basina M, Dosiou C, I. Ross McDougall. Post-Surgical ^{131}I Ablation in Patients with Papillary Thyroid Cancer: The Role of Diagnostic ^{123}I Whole Body Scan. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.
60. Davidzon G, Mosci C, Mittra ES, Shin B, Chin F, Gambhir SS, **Iagaru A**. Biodistribution and Kinetics of ^{18}F FPPRGD₂ PET/CT in the Evaluation of Suspected Recurrence in Glioblastoma Multiforme. ACNM/SNMMI Mid-Winter Meeting, New Orleans, LA. Jan 24-27, 2013.
61. Keu KV, Mittra E, Quon A, **Iagaru A**. Pre-Treatment ^{18}F FDG PET/CT Findings Can Not Predict Late Recurrence of Nasopharyngeal Carcinoma. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
62. Keu KV, Mittra E, Quon A, **Iagaru A**. The Value of Post-Therapy ^{18}F FDG PET/CT Surveillance Scans in the Detection of Recurrent Nasopharyngeal Carcinoma. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
63. Mosci C, Akatsu H, Basina M, Dosiou C, McDougall IR, **Iagaru A**. Implications of ^{123}I Whole Body Scan Pre-Ablation of Thyroid Remnant in Papillary Thyroid Cancer Patients. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
64. Mosci C, Ganjoo K, Norton J, Mittra E, Quon A, **Iagaru A**. The Value of ^{18}F FDG PET/CT in the Evaluation of Soft Tissue Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
65. Mosci C, Marina N, Ganjoo K, Mohler D, Avedian R, Mittra E, Quon A, **Iagaru A**. ^{18}F FDG PET/CT and Dedicated CT in the Evaluation of Bone Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
66. Mosci C, Marina N, Mittra E, Quon A, **Iagaru A**. ^{18}F FDG PET/CT Evaluation of Pediatric Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
67. Davidzon G, Mosci C, Mittra E, Shen B, Chin F, Gambhir SS, **Iagaru A**. Biodistribution and Kinetics of ^{18}F FPPRGD₂ in Cancer Patients. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
68. Hope T, Keu KV, Robb F, Herfkens R, **Iagaru A**. Effect of Anterior Body MRI Coils on PET Acquisitions and Evaluation of a Novel Minimally Attenuating PET/MR Coil. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.
69. **Iagaru A**, Davidzon G, Mosci C, Shen B, Chin FT, Gambhir SS. Pilot Prospective Evaluation of the Novel PET/CT Radiopharmaceutical ^{18}F FPPRGD₂ in Patients with Non-Small Cell Lung Cancer. WMIS Annual Congress, Savannah, GA. Sep 18-21, 2013.
70. **Iagaru A**, Davidzon G, Mosci C, Kumar M, Shen B, Chin FT, Gambhir SS. Pilot Prospective Evaluation of Early Response to Bevacizumab Treatment Using the Novel PET/CT Radiopharmaceutical ^{18}F FPPRGD₂. EANM Annual Congress, Lyon, France. Oct 19-23, 2013.
71. Keu KV, Lutchan G, Quon A, Mittra ES, **Iagaru A**. The Role of $^{99\text{m}}\text{Tc}$ -MDP Bone Scintigraphy in the Workup of Patients with Hepatocellular Carcinoma. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2013.
72. Keu KV, Twist C, Quon A, Mittra ES, **Iagaru A**. Semi-quantitative Evaluation of Neuroblastoma Tumor Burden Using ^{123}I mIBG and ^{18}F FDG PET/CT. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2013.

73. Jackson T, Mosci C, von Eyben R, Mittra ES, Ganjoo K, Biswal S, Gambhir SS, **Iagaru A**. Combined ¹⁸F NaF and ¹⁸F FDG PET/CT in the Evaluation of Sarcoma Patients. ACNM/SNMMI Mid-Winter Meeting, Palm Springs, CA. Feb 6-9, 2014.
74. **Iagaru A**, Mosci C, Jamali M, Minamimoto R, Mittra ES, Shin B, Chin F, Gambhir SS. ¹⁸F FPPRGD₂ PET/CT Evaluation Of Patients With Suspected Recurrence Of Glioblastoma Multiforme. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
75. **Iagaru A**, Mittra ES, Zaharchuk G, Prost RW, Elekes A, Anderson J, Bobb C, Lahrman J, Gold GE, Gambhir SS. ¹⁸F FDG SUVmax Values in Normal Tissues and Malignant Lesions from the First Time-of-Flight Whole-Body PET/MRI Scanner: Comparison with Values from PET/CT. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
76. Castaneda P, Leonard Z, Wen M, Kwofie J, Mittra ES, **Iagaru A**. Initial Experience with ²²³Ra Vial Delivery (Alpharadin[®]) vs. Unit-Dose Delivery (Xofigo[®]). SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
77. **Iagaru A**, Mosci C, Jamali M, Loening A, Mittra ES, Gambhir SS, Vasawala SS. Prospective Evaluation of Combined ¹⁸F NaF/¹⁸F FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
78. **Iagaru A**, Mosci C, Jamali M, Loening A, Mittra ES, Gambhir SS, Vasawala SS. Prospective Evaluation of Combined ¹⁸F NaF/¹⁸F FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. WFNMB Congress, Cancun, Mexico. Aug 27-31, 2014.
79. **Iagaru A**, Jamali M, Minamimoto R, Mittra ES, Gold GE, Vasawala S, Gambhir SS, Zaharchuk G. First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT. WFNMB Congress, Cancun, Mexico. Aug 27-31, 2014.
80. **Iagaru A**, Mosci C, Keu KV, Mittra ES, Hancock S, Pachynski R, Srinivas S, Gambhir SS ¹⁸F NaF and ¹⁸F FDG PET/CT for Evaluation of Prostate Cancer Patients. WMIS Annual Congress, Seoul, Korea. Sep 17-20, 2014.
81. **Iagaru A**, Jamali M, Minamimoto R, Mittra ES, Gold GE, Vasawala S, Gambhir SS, Zaharchuk G. First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT. EANM Annual Congress, Stockholm, Sweden. Oct 18-22, 2014.
82. **Iagaru A**, Mosci C, Jamali M, Barkhodari A, Minamimoto R, Loening A, Mittra ES, Gambhir SS, Vasawala SS. Prospective Evaluation of Combined ¹⁸F NaF/¹⁸F FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. WRSNM Annual Meeting, Seattle, WA. Oct 30 - Nov 2, 2014.
83. Sabbah N, Jackson T, Mosci C, Jemali M, Minamimoto R, Quon A, **Iagaru A**. Characterization of ¹⁸F-NaF Uptake in Normal Bone, Bone Metastases, Degenerative Changes and Extra-Skeletal Tissues: An Atlas of Standardized Uptake Values. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.
84. Minamimoto R, **Iagaru A**, Jamali M, Holley D, Vasawala S, Herfkens, R Sawyer AM, Glover G, Gambhir SS, Zaharchuk G. Whole-body Simultaneous Time-of-Flight PET-MRI: Initial Clinical Experience. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.
85. Thompson H, Jamali M, Minamimoto R, Barkhodari A, Quon A, Mittra ES, **Iagaru A**. SUV Values in Cancer Lesions: A Prospective, Matched Comparison of Data from Non-TOF vs. TOF PET/CT Scanners. ACNM/SNMMI Mid-Winter Meeting, San Antonio, TX. Jan 22-25, 2015.
86. Minamimoto R, Levin CS, Jamali M, Barkhodari A, Holley D, Zaharchuk G, **Iagaru A**. The potential of TOF PET-MRI for reducing artifacts in PET images. 4th Conference on PET/MR and SPECT/MR, Isola d'Elba, Italy. May 17-21, 2015.
87. **Iagaru A**, Minamimoto R, Jamali M, Barkhodari A, Gambhir SS, Vasawala SS. Imaging Patients with Breast and Prostate Cancers Using Combined ¹⁸F NaF/¹⁸F FDG and TOF simultaneous PET/ MRI. 4th Conference on PET/MR and SPECT/MR, Isola d'Elba, Italy. May 17-21, 2015.

88. **Iagaru A**, Minamimoto R, Mosci C, Jamali M, Barkhodari A, Loening AM, Taviani V, Mitra E, Gambhir SS, Vasanaawala S. Prospective evaluation of ^{99m}Tc MDP scintigraphy, ^{18}F NaF/ ^{18}F FDG PET/CT and WBMRI in patients with breast and prostate cancers. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.
89. **Iagaru A**, Minamimoto R, Jamali M, Barkhodari A, Obara P, Loening AM, Taviani V, Mitra E, Gambhir SS, Vasanaawala S. Imaging patients with breast and prostate cancers using combined ^{18}F NaF/ ^{18}F FDG and TOF simultaneous PET/MRI. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.
90. Lantos J, Mitra E, Levin CS, **Iagaru A**. Standard OSEM vs. regularized PET image reconstruction: qualitative and semi-quantitative comparison. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.
91. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mitra E, Shen B, Chin F, Gambhir SS, **Iagaru A**. ^{18}F -FPFRGD₂ PET as a Surrogate Biomarker of Integrin $\alpha_v\beta_3$ Expression Before and After Anti-angiogenesis Treatment. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.
92. **Iagaru A**, Minamimoto R, Jamali M, Barkhodari A, Gambhir SS, Vasanaawala SS. Combined ^{18}F NaF/ ^{18}F FDG and TOF simultaneous PET/ MRI in patients with breast and prostate cancer. WMIS Annual Congress, Honolulu, HI. Sep 2-5, 2015.
93. Xu G, Minamimoto R, Quon A, Mitra E, **Iagaru A**. Semi-quantitative assessment of ^{18}F FDG uptake in the normal skeleton using simultaneous PET/MRI: initial comparison to PET/CT in 50 patients. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
94. Minamimoto R, Jamali M, Barkhodari A, Holley D, Zaharchuk G, Levin C, **Iagaru A**. Improvements in PET Image quality from TOF PET/MRI. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
95. **Iagaru A**, Lantos J, Mitra EM, Levin C. Standard OSEM vs. Regularized PET Image Reconstruction: Qualitative and Semi-Quantitative Comparison. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
96. Minamimoto R, Loening A, Obara P, Taviani V, Gambhir SS, Vasanaawala S, **Iagaru A**. Combined ^{18}F NaF/ ^{18}F FDG and TOF simultaneous PET/ MRI: One-Stop Shop Staging of Patients with Breast and Prostate Cancers. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.
97. **Iagaru A**, Minamimoto R, Schneider B, Chin FT, Mitra ES, Taviani V, Vasanaawala S, Mueller A, Berndt M, Stephens A, Gambhir SS. Pilot Prospective Evaluation of ^{68}Ga -DOTA-Bombesin (^{68}Ga -RM2 or ^{68}Ga -Bombesin) with TOF PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. WRSNM Annual Meeting, Monterey, CA. Oct 22-25, 2015.
98. Minamimoto R, Loening AM, Taviani V, Gambhir SS, Vasanaawala SS, Iagaru A. Imaging Patients with Breast and Prostate Cancers Using Combined ^{18}F NaF/ ^{18}F FDG and TOF simultaneous PET/ MRI. RSNA Annual Meeting, Chicago, IL. Nov 29 - Dec 5, 2015.
99. **Iagaru A**, Minamimoto R, Hancock S, Mitra ES, Loening A, Vasanaawala S, Gambhir SS. ^{68}Ga -DOTA-Bombesin (^{68}Ga -RM2 or ^{68}Ga -Bombesin) PET vs. ^{68}Ga -PSMA PET: A Pilot Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. ASCU GU Symposium, San Francisco, CA. Jan 7-9, 2016.
100. **Iagaru A**, Minamimoto R, Loening A, Mueller A, Berndt M, Stephens A, Vasanaawala S. Biochemically Recurrent Prostate Cancer: ^{68}Ga -DOTA-Bombesin (^{68}Ga -RM2 or ^{68}Ga -Bombesin) PET/MRI Is Superior to Conventional Imaging. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.
101. **Iagaru A**, Minamimoto R, Loening A, Vasanaawala S, Gambhir SS. ^{68}Ga -DOTA-Bombesin (^{68}Ga -RM2 or ^{68}Ga -Bombesin) PET vs. ^{68}Ga -PSMA PET: A Pilot Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.
102. Wu F, Jamali M, Hatami N, Sonni I, Baratto L, Guo HH, Quon A, Mitra E, **Iagaru A**. ^{99m}Tc -MDP scintigraphy vs. ^{18}F -NaF PET/CT for detection of skeletal metastases. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.

103. **Iagaru A**, Minamimoto R, Loening A, Mueller A, Berndt M, Stephens A, Vasanaawala S. Biochemically recurrent prostate cancer: ^{68}Ga -RM2 (formerly known as ^{68}Ga -Bombesin or BAY86-7548) PET/MRI is superior to conventional imaging. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.
104. Deller T, Khalighi MM, Lantos J, Gulaka P, **Iagaru A**. Evaluation of improved scatter correction with highly targeted ^{68}Ga -labeled radiopharmaceuticals. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.
105. **Iagaru A**, Sonni I, Minamimoto R, Loening A, Vasanaawala S. ^{68}Ga -RM2 PET/MRI Evaluation of Gastrin-Releasing Peptide Receptors Status in Biochemically Recurrent Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2016.
106. ^{18}F NaF/ ^{18}F FDG simultaneous PET/ MRI with TOF in patients with breast and prostate cancers. Sonni I, Minamimoto R, Loening AM, Taviani V, Gambhir SS, Vasanaawala SS, **Iagaru A**. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2016.
107. Sonni I, Minamimoto R, Loening A, Vasanaawala S, **Iagaru A**. ^{68}Ga -RM2 PET/MRI in biochemically recurrent prostate cancer: a comparison with conventional imaging. RSNA Annual Meeting, Chicago, IL. Nov 27 - Dec 3, 2016.
108. Harrison C, Sonni I, Loening A, Vasanaawala S, **Iagaru A**. ^{68}Ga -RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. ACNM/SNMMI Mid-Winter Meeting, Phoenix, AR. Jan 18-22, 2017.
109. Sonni I, Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. Initial Experience with a SiPM-based PET/CT Scanner: Influence of Acquisition Time on Image Quality. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
110. Zacharias C, Harrison C, Ghanouni P, Sonn G, **Iagaru A**. ^{68}Ga PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate and High-Risk Prostate Cancers. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
111. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. Initial Experience with a New PET/CT System Using SiPM Detectors: Image Quality Comparison with Standard PET/CT. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
112. Harrison C, Sonni I, Loening A, Vasanaawala S, **Iagaru A**. Detection of Recurrent Prostate Cancer Using ^{68}Ga -RM2 PET/MRI in Patients with Negative Conventional Imaging. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
113. Sonni I, Minamimoto R, Taviani V, Hatami N, Gambhir SS, Vasanaawala S, **Iagaru A**. Imaging Patients with Breast and Prostate Cancers Using Combined ^{18}F NaF/ ^{18}F FDG and TOF simultaneous PET/ MRI. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
114. Gandhi H, Holley D, Gulaka P, **Iagaru A**. ^{68}Ga PSMA-11 PET/MRI: Influence of Acquisition Time on Image Quality. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
115. Baratto L, Park S, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
116. Park S, Baratto L, Gulaka P, Herfkens R, Witteles R, **Iagaru A**. Florbetaben Whole-Body PET/MRI for Evaluation of Systemic Amyloid Deposition. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.
117. Park S, Zacharias C, Harrison C, Baratto L, Hatami N, **Iagaru A**. ^{68}Ga -PSMA-11 PET/MRI in Primary Intermediate / High-Risk Prostate Cancer. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.
118. Park S, Baratto L, Gandhi H, Gulaka P, **Iagaru A**. ^{68}Ga -PSMA-11 PET/MRI: Influence of Scan Time on Image Quality. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

119. Sonni I, Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. First Experience with Fast Imaging Using Discovery MI PET/CT. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.
120. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Nair V, **Iagaru A**. Improved Pulmonary Nodule Detection Using a Next Generation ¹⁸F-FDG PET Imaging System. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.
121. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. Initial Experience with a New PET/CT System Using SiPM Detectors. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.
122. Baratto L, Park S, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.
123. Park S, Zacharias C, Harrison C, Baratto L, Hatami N, **Iagaru A**. ⁶⁸Ga-PSMA PET/MRI in Primary Intermediate / High-Risk Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.
124. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Nair V, **Iagaru A**. Improved Pulmonary Nodule Detection Using a Next Generation ¹⁸F-FDG PET Imaging System. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.
125. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. Initial Experience with a New PET/CT System Using SiPM Detectors. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.
126. Baratto L, Park S, Hatami N, Davidzon G, Srinivas S, Gambhir SS, **Iagaru A**. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.
127. Moradi F, **Iagaru A**. Diagnostic Performance Of ⁶⁸Ga-DOTATATE PET/CT in Evaluation of Neuroendocrine Malignancies: What Parameters Are Useful? RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.
128. Song H, Harrison C, Tu P, Yohannan TK, Davidzon G, **Iagaru A**. ¹⁸F FDG PET/CT Evaluation of Patients with Breast Cancer. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 25-27, 2018.
129. Park S, Hatami N, Baratto L, Yohannan T, Davidzon G, **Iagaru A**. Dual-Time ⁶⁸Ga-PSMA-11 Imaging for Biochemically Recurrent Prostate Cancer Using LYSO and SiPM-Based Detectors PET/CT. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 25-27, 2018.
130. Duan H, Khalaf MH, Baratto L, Sze DY, Srinivas S, **Iagaru A**. High Quality Imaging and Dosimetry of Yttrium-90 (⁹⁰Y) Radioembolization Using a SiPM-Based PET/CT scanner. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.
131. Baratto L, Toriihara A, Hatami N, Davidzon G, Srinivas SS, Gambhir SS, **Iagaru A**. SiPM-based vs LYSO-based ⁶⁸Ga-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.
132. Baratto L, Duan H, Gandhi H, Kalighi M, Gulaka P, **Iagaru A**. The effect of various beta values on image quality and semi-quantitative measurements in ⁶⁸Ga-labeled GRPR and PSMA PET/MRI images reconstructed with a block sequential regularized expectation maximization algorithm. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.
133. Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz P, **Iagaru A**. Prognostic value of volumetric parameters calculated from ⁶⁸Ga-DOTA TATE PET/CT in patients with well-differentiated neuroendocrine tumors. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.
134. Toriihara A, Duan H, Park S, Hatami N, Baratto L, Fan A, **Iagaru A**. ¹⁸F-FPPRGD₂ PET/CT in patients with metastatic renal cell cancer. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.
135. Baratto L, Harrison C, Davidzon G, Yohannan T, **Iagaru A**. ⁶⁸Ga-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

136. Song H, Yohannan T, Srinivas S, Vasawala S, **Iagaru A**. Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.
137. Barrato L, Duan H, Mari C, Davidzon G, **Iagaru A**. ⁶⁸Ga-RM2 + ⁶⁸Ga-PSMA-11 PET: Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. WMIS Annual Congress, Seattle, WA. Sep 12-15, 2018.
138. Baratto L, Duan H, Harrison C, Mari C, Davidzon G, Yohannan T, **Iagaru A**. ⁶⁸Ga-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. EANM Annual Congress, Dusseldorf, Germany. Oct 13-17, 2018.
139. Barrato L, Duan H, Minamimoto R, Mari C, Yohannan T, Davidzon G, **Iagaru A**. ⁶⁸Ga-RM2 PET vs. ⁶⁸Ga-PSMA-11 PET: Prospective Comparison in Patients with Biochemical Recurrence of Prostate Cancer. EANM Annual Congress, Dusseldorf, Germany. Oct 13-17, 2018.
140. Barrato L, Duan H, Hatami N, Yohannan T, Mari C, Davidzon G, **Iagaru A**. Dual-Time ⁶⁸Ga-RM2 Imaging for Staging Patients with Newly Diagnosed Intermediate or High-Risk Prostate Cancer Using PMT and SiPM-Based Detectors PET/CT. EANM Annual Congress, Dusseldorf, Germany. Oct 13-17, 2018.
141. Baratto L, Duan H, Gandhi H, Kalighi M, Gulaka P, **Iagaru A**. The effect of various beta values on image quality and semi-quantitative measurements in ⁶⁸Ga-labeled GRPR and PSMA PET/MRI images reconstructed with a block sequential regularized expectation maximization algorithm. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.
142. Baratto L, Duan H, Torihara A, Hatami N, Parker S, Nobashi T, **Iagaru A**. Standardized uptake value atlas: physiological and abnormal ⁶⁸Ga-RM2 uptake in patients with prostate cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.
143. Baratto L, Harrison C, Davidzon G, Yohannan T, **Iagaru A**. ⁶⁸Ga-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.
144. Torihara A, Nobashi T, Baratto L, Park S, Hatami N, Duan H, Mari C, Davidzon G, Yohannan T, **Iagaru A**. Inter-Reader and Inter-Criteria Agreement for Evaluation of ⁶⁸Ga-PSMA PET. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.
145. Duan H, Khalaf M, Baratto L, Srinivas S, Sze D, **Iagaru A**. High Quality Imaging and Dosimetry of Yttrium-90 (⁹⁰Y) Radioembolization Using a SiPM-Based PET/CT scanner. RSNA Annual Meeting. Chicago, IL. Nov 25-30, 2018.
146. Duan H, Park S, Baratto L, Hatami N, Khalaf HM, Yohannan T, Davidzon G, **Iagaru A**. Dual-Time ⁶⁸Ga-PSMA-11 Imaging for Biochemically Recurrent Prostate Cancer Using LYSO and SiPM-Based Detectors PET/CT. RSNA Annual Meeting. Chicago, IL. Nov 25-30, 2018.
147. Baratto L, Torihara A, Hatami N, Davidzon G, Srinivas SS, Gambhir SS, **Iagaru A**. SiPM-Based versus LYSO-based ⁶⁸Ga-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions. RSNA Annual Meeting. Chicago, IL. Nov 25-30, 2018.
148. Harrison C, Song H, Mari Aparici C, Davidzon G, **Iagaru A**. Initial Clinical Experience Using ¹⁸F-Fluciclovine PET/CT at an Academic Center: Positivity Rate and Correlation with PSA levels. ACNM/SNMMI Mid-Winter Meeting, Palm Springs, CA. Jan 17-19, 2019.
149. Song H, Harrison C, Davidzon G, Mari Aparici C, **Iagaru A**. Academic Center Comparison of ¹⁸F-Fluciclovine PET/CT and Other Imaging Modalities in Biochemically Recurrent Prostate Cancer. ACNM/SNMMI Mid-Winter Meeting, Palm Springs, CA. Jan 17-19, 2019.
150. Harrison C, Song H, Duan H, Davidzon G, **Iagaru A**. Prospective evaluation of ¹⁸F- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer. AUA Annual Meeting, Chicago, IL. May 3-6, 2019.
151. Song H, Harrison C, Guja K, Franc B, Moradi F, Davidzon G, Mari Aparici C, **Iagaru A**. Prospective evaluation of ¹⁸F- DCFPyL and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

152. Baratto L, Duan H, Hatami N, Toriihara A, Song H, **Iagaru A**. Prospective evaluation of ^{68}Ga -RM2 PET/MRI and ^{68}Ga -PSMA11 PET/CT in patients with biochemical recurrence of prostate cancer. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.
153. Moradi F, Guja K, Mari Aparici C, **Iagaru A**. Quantification of uptake in ^{68}Ga -DOTATATE PET: Correlation between standardized uptake values and patient factors. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.
154. Toriihara A, Nobashi T, Baratto L, Park S, Hatami N, Duan H, Mari Aparici C, Davidzon G, **Iagaru A**. Comparison of three interpretation criteria of ^{68}Ga -PSMA PET based on inter- and intra-reader agreement. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.
155. Duan H, Song H, Baratto L, Khalaf M, Hatami N, Franc B, Moradi F, Davidzon G, Mari Aparici C, **Iagaru A**. Prospective Comparison of ^{18}F -DCFPyL PET/CT with ^{18}F -NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.
156. Duan H, Khalaf M, Baratto L, Srinivas S, Sze D, **Iagaru A**. Clinical Follow-Up after Imaging and Dosimetry for Yttrium-90 (^{90}Y) Liver Radioembolization Using a SiPM-Based PET/CT Scanner. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.
157. Harrison C, Song H, Franc B, Guja K, Moradi F, Davidzon G, Mari Aparici C, **Iagaru A**. Prospective evaluation of ^{18}F -DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.
158. Baratto L, Duan H, Harrison C, Hatami N, Mari Aparici C, Davidzon G, Yohannan T, **Iagaru A**. Preliminary Results of a Prospective Study of ^{68}Ga -RM2 PET/MRI for Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.
159. Song H, Kunz PL, Franc B, Moradi F, Davidzon G, **Iagaru A**, Mari Aparici C. Comparison of ^{68}Ga -DOTA-TATE PET/CT for assessment of response to peptide receptor radionuclide therapy after 2 and 4 cycles of Lutathera[®]: preliminary single academic center experience. NANETS Multidisciplinary NET Medical Symposium, Boston, MA. Oct 3-5, 2019.
160. Baratto L, Duan H, Davidzon G, **Iagaru A**. ^{68}Ga -RM2 PET Imaging for Staging Patients with Newly Diagnosed Intermediate or High-Risk Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 12-16, 2019.
161. Duan H, Song H, Harrison C, Guja K, Franc B, Moradi F, Mari Aparici C, Davidzon G, **Iagaru A**. Prospective evaluation of ^{18}F -DCFPyL in Patients with Biochemically Recurrent Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 12-16, 2019.
162. Davidzon G, Lee J, Yang H, Song H, Harrison C, **Iagaru A**. Machine Learning to Detect Prostate Cancer Recurrence using ^{18}F -Fluciclovine PET. EANM Annual Congress, Barcelona, Spain. Oct 12-16, 2019.
163. Duan H, Khalaf MH, Baratto L, Srinivas S, Sze DY, **Iagaru A**. Clinical Follow-Up after Imaging and Dosimetry for Yttrium-90 (^{90}Y) Liver Radioembolization Using a SiPM-Based PET/CT Scanner. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.
164. Baratto L, Duan H, Harrison C, Mari C, Davidzon G, Moradi F, **Iagaru A**. Interim Analysis Results of a Prospective Study of ^{68}Ga -RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.
165. Duan H, Song H, Baratto L, Hatami N, Franc BL, Moradi F, Davidzon G, Mari Aparici C, **Iagaru A**. Prospective Comparison of ^{18}F -DCFPyL PET/CT with ^{18}F -NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.
166. Hong S, Harrison C, Guja KE, Franc BL, Moradi F, Davidzon H, Mari Aparici C, **Iagaru A**. Comparison of ^{18}F -Fluciclovine PET/CT with Conventional Imaging in Prostate Cancer Patients with Biochemical Recurrence. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.

167. Baratto L, Song H, Duan H, Mari Aparici C, Hatami N, Davidzon G, Moradi F, **Iagaru A**. Interim Analysis Results of a Prospective Study of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. AUA Virtual Annual Meeting, May 15-19, 2020.
168. Song H, Duan H, Harrison C, Guja K, Hatami N, Franc B, Moradi F, Mari Aparici C, Davidzon G, Srinivas S, **Iagaru A**. Prospective evaluation of ¹⁸F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: analysis of lesion localization and distribution. ASCO Virtual Annual Meeting, May 29-31, 2020.
169. Leonard Z, Ramos K, Nguyen V, Castaneda P, **Iagaru A**. SUV measurements from images reconstructed with the block sequential regularized expectation maximization algorithm: comparison of motion corrected vs. non-motion corrected data. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.
170. Baratto L, Duan H, Hatami N, Mari Aparici C, Davidzon G, **Iagaru A**. ⁶⁸Ga-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.
171. Moradi F, Baratto L, Duan H, Hatami N, Davidzon G, Sonn G, **Iagaru A**. ⁶⁸Ga-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.
172. Duan H, Hatami N, Baratto L, Davidzon G, Mari Aparici C, Gambhir SS, Koglin N, Witteles R, **Iagaru A**. A pilot study of ¹⁸F-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic ¹⁸F-FDG PET/CT. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.
173. Baratto L, Song H, Duan H, Davidzon G, Moradi F, **Iagaru A**. Preliminary Results of a Prospective Study of ⁶⁸Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. WMIS Virtual Congress, Oct 7-9, 2020.
174. Duan H, Gambhir SS, Koglin N, Witteles R, **Iagaru A**. A pilot study of ¹⁸F-FSPG PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative, equivocal or non-diagnostic ¹⁸F-FDG PET/CT. WMIS Virtual Congress, Oct 7-9, 2020.
175. Baratto L, Song H, Duan H, Davidzon G, Moradi F, **Iagaru A**. ⁶⁸Ga-RM2 Gastrin-Releasing Peptide Receptors PET Imaging for Biochemically Recurrent Prostate Cancer in the Era of PSMA: Results of a Prospective Study. EANM Virtual Congress, Oct 23-30, 2020.
176. Song H, Duan H, Harrison C, Guja K, Hatami N, Franc B, Moradi F, Mari Aparici C, Davidzon G, **Iagaru A**. Prospective Single Institution Study of ¹⁸F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: An Analysis of Lesions Detection and Localization. EANM Virtual Congress, Oct 23-30, 2020.
177. Duan H, Hatami N, Baratto L, Davidzon G, Mari Aparici C, Gambhir SS, Koglin N, Witteles R, **Iagaru A**. Preliminary Results of ¹⁸F-FSPG PET/CT in Patients Referred for Exclusion of Active Cardiac Sarcoidosis after Non-Contributory ¹⁸F-FDG PET/CT. EANM Virtual Congress, Oct 23-30, 2020.

G. Research

1. Active

5U01CA21002002 Iagaru (PI) 05/01/2017-04/30/2022
 National Institutes of Health (Project 122878)
 Molecular Imaging Methods for the Detection of Pancreatic Ductal Adenocarcinoma.
 The major goal is to evaluate new strategies for early detection of prostate cancer.
 Role: Principal Investigator

A206T-G01-001 Iagaru (PI) 11/15/2018 - 11/30/2021
Advanced Accelerator Applications USA, Inc.
A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of ¹⁷⁷Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive (⁶⁸Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic treatment^[17]
Role: Principal Investigator

PSMA-617-01 Srinivas (PI) 12/07/2018 - 12/31/2021
Endocyte, Inc.
An International, prospective, open-label, multicenter, randomized phase 3 study of ¹⁷⁷Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (MCRPC) of ¹⁷⁷Lu-PSMA617
Role: Co-Investigator

W81XWH-16-1-0604 Iagaru (PI) 09/30/2016 - 09/29/2021
Department of Defense, Project 121943
⁶⁸Ga Bombesin PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Noncontributory Conventional Imaging
The major goal of this project is to evaluate a new PET radiopharmaceutical for detection of recurrent prostate cancer
Role: Principal Investigator

1R01 CA23868601A1 Rosenthal (PI) 12/15/2019 - 11/30/2021
National Institutes of Health, Project 137829
Next Generation Sentinel Node Mapping
The major goal of this project is to evaluate ⁸⁹Zr-Panitumumab as a novel PET radiopharmaceutical for sentinel lymph node mapping in head and neck cancers. Successful application of this technique to head and neck cancers could have implications for other tumor types for which lymph node status plays an important role.
Role: Co-Investigator

1R01 CA230438-01A1 Iagaru (PI) 08/01/2019 - 07/31/2024
National Cancer Institute, Project 133164
Evaluation of Patients with Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using ⁶⁸Ga-RM2 PET, ⁶⁸Ga-PSMA-11 PET and Multi Parametric MRI
The major goal of this project is to evaluate the use of ⁶⁸Ga-RM2 PET/MRI and ⁶⁸Ga-PSMA-11 PET/MRI to guide high-dose rate brachytherapy, evaluate response and predict progression-free survival in men with intermediate-risk prostate cancer.
Role: Principal Investigator

2. Completed

Source: ART
Title: Adjunctive Efficacy Study of the SoftScan Optical Breast Imaging System
Role: Co-Investigator
Period Covered: 2006 - 2009
Goal: To investigate a novel optical scanner for detection of malignant breast lesions

Source: Genentech
Title: PET Imaging of Lymphoma Patients Using Radiolabeled Rituximab
Role: Co-Investigator
Period Covered: 2007 - 2009
Goal: To develop a novel radiopharmaceutical for PET imaging of lymphoma patients

Source: Stanford Cancer Institute
Title: ¹⁸F FPPRGD₂ PET/CT in Patients with Breast Cancer
Role: Principal Investigator
Period Covered: 2010 - 2011
Goal: To evaluate ¹⁸F FPPRGD₂ PET/CT in breast cancer

Source: Ivy Foundation
 Title: ^{18}F FPPRGD₂ PET/CT, ^{18}F FDG PET/CT and MRI Evaluation of Response to Anti-Angiogenesis Therapy in Recurrent Glioblastoma Multiforme
 Role: Co-Investigator
 Period Covered: 2010 - 2016
 Goal: To evaluate a new integrin receptor PET radiopharmaceutical for evaluation of response to anti-angiogenesis therapy in patients with recurrent GBM

Source: NIH (ICMIC P50)
 Title: Monitoring Response to Targeted Therapy in Non-Small Cell Lung Cancer using ^{18}F FPPRGD₂ PET/CT and *In-Vitro* Diagnostics
 Role: Co-Investigator (PI: Sanjiv Sam Gambhir)
 Period Covered: 2010 - 2015
 Goal: To evaluate a new integrin receptor PET radiopharmaceutical for evaluation of response to anti-angiogenesis therapy in patients with NSCLC

Source: GE Healthcare
 Title: Comparison of Combined ^{18}F NaF/ ^{18}F FDG PET/CT and WBMRI for Skeletal Metastases Detection
 Role: Principal Investigator
 Period Covered: 2012 - 2014
 Goal: To evaluate PET/CT and WBMRI in detection of skeletal metastases

Source: Stanford Cancer Institute
 Title: ^{18}F FPPRGD₂ PET/CT in Patients with Sarcoma
 Role: Principal Investigator
 Period Covered: 2012 - 2013
 Goal: To evaluate ^{18}F FPPRGD₂ PET/CT in angiosarcoma

Source: Department of Radiology, Stanford University
 Title: PET Imaging of Lymphoma Patients Using Radiolabeled Rituximab
 Role: Principal Investigator
 Period Covered: 2012 - 2013
 Goal: To test a novel radiopharmaceutical for PET imaging of lymphoma patients

Source: Bayer Healthcare
 Title: Alpharadin in Castration-Resistant (Hormone Refractory) Prostate Cancer Patients with Bone Metastases
 Role: Principal Investigator
 Period Covered: 2012 - 2014
 Goal: To test a novel radiopharmaceutical for therapy of bone metastases

Source: Piramal Imaging, GmbH
 Title: ^{68}Ga -RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging
 Role: Principal Investigator
 Period Covered: 2015 - 2016
 Goal: To evaluate a new gastrin releasing peptide receptor PET radiopharmaceutical for evaluation of disease extent in patients with recurrent prostate cancer

Source: Bayer Healthcare
 Title: Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Ra-223 in mCRPC Patients
 Role: Principal Investigator
 Period Covered: 2015 - 2017
 Goal: To test a novel diagnostic approach for evaluation of response to therapy of bone metastases

Source: GE Healthcare
 Title: External Validation of the Next Generation PET/CT System
 Role: Principal Investigator

Period Covered: 2016 - 2017
 Goal: To test a novel PET/CT scanner

Source: GE Healthcare
 Title: Combined ^{18}F NaF/ ^{18}F FDG PET/MRI for Skeletal Metastases Detection
 Role: Principal Investigator
 Period Covered: 09/2014 - 08/2018
 Goal: To evaluate PET and MRI in detection of skeletal metastases

Source: GE Healthcare
 Title: PET/MRI of Cardiac Amyloid
 Role: Principal Investigator
 Period Covered: 09/2016 - 08/2018
 Goal: To test a novel radiopharmaceutical for PET imaging of patients with suspected cardiac amyloid

Source: GE Healthcare
 Title: PET/MRI of Cardiac Sarcoid
 Role: Principal Investigator
 Period Covered: 09/2016 - 08/2018
 Goal: To test a novel radiopharmaceutical for PET imaging of patients with suspected cardiac sarcoid

Source: GE Healthcare
 Title: ^{68}Ga -PSMA PET/MRI in Patients with Newly Diagnosed Intermediate and High-Risk Prostate Cancer
 Role: Principal Investigator
 Period Covered: 09/2016 - 08/2018
 Goal: To evaluate a new prostate specific membrane antigen PET radiopharmaceutical for evaluation of disease extent in patients with recurrent prostate cancer

Source: GE Healthcare
 Title: Advanced Research for Digital PET/CT
 Role: Principal Investigator
 Period Covered: 09/2016 - 02/2020
 Goal: is to evaluate the new SiPM-based PET detectors in various clinical applications

Source: National Institutes of Health (Project 117724)
 Title: Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD)
 Role: Co-Investigator
 Period Covered: 09/2015 - 07/2020
 Goal: The major goal of this project is to develop in vitro diagnostics and in vivo molecular imaging using novel nanotechnology strategies. Included are cell sorting and cell analysis technologies as well as self-assembling nanoparticles and nano bubbles.